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resumo 
 
 
Na pele surgem dois dos tipos mais comuns de cancro epitelial, o carcinoma 
basocelular (BCC) e o carcinoma escamoso da pele (SCC). Neste trabalho, 
investigámos como ASPP2, membro da família de proteínas que interage com 
a família p53, pode afectar a tumurigénese da pele. Estudou-se a regulação 
por ASPP2 das vias de sinalização envolvidas na homeostasia normal do 
tecido epitelial, tais como as vias de p63 e Notch. A activação anormal de 
ΔNp63 no epitélio é uma causa conhecida para o surgimento do SCC e os 
nossos resultados indicam que a ASPP2 é importante a limitar a expressão de 
ΔNp63 no epitélio diferenciado, prevenindo a proliferação das células na pele. 
Para além disso, observámos que ASPP2 coopera com vias de sinalização 
pró-diferenciação, tais como as de Notch e p73. Os nossos resultados 
mostram um possível mecanismo pelo qual a expressão de p63 pode ser 
regulada na pele e sugerem um novo modelo para a formação espontânea de 
SCC. 
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abstract 
 
The skin is where two of the most common types of epithelial cancer, basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC), arise. In this work, we 
have investigated how ASPP2, a member of a family of proteins that interact 
with the p53 family, can affect skin tumourigenesis. We analysed the regulation 
of ASPP2 in pathways involved in the normal homeostasis of the epithelium, 
such as the p63 and Notch. Aberrant or misplaced activation of ΔNp63 in the 
epithelium is a known initiating cause for SCC and our results indicate that 
ASPP2 is important in limiting ΔNp63 expression in the differentiated 
epithelium, preventing cell proliferation in the skin. Additionally, we found that 
ASPP2 can cooperate with skin pro-differentiation pathways, such as Notch 
and p73. Overall, our results indicate a possible mechanism by which p63 
expression can be regulated in the skin, and provide a new model for the 
spontaneous formation of SCC.  
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Thesis outline 
In this work, we have investigated how ASPP2, a member of a family of proteins that interact 
with the p53 family, can affect skin tumourigenesis. ASPP2 is expressed in the squamous 
epithelia of various organs, and is exclusively to the upper and most differentiated layers. To 
investigate the observation that the absence of ASPP2 from the epithelial compartment leads to 
tumour formation, we analysed ASPP2’s relationship with pathways involved in the normal 
homeostasis of the epithelium, such as p63 and Notch. ΔNp63 is the main p63 isoform 
expressed in the adult epidermis, and its function is to drive the proliferation of the basal 
keratinocytes. Aberrant or misplaced activation of ΔNp63 in the epithelium is a known 
initiating cause for Squamous cell carcinoma (SCC). Consistent with this, ΔNp63 was found to 
be highly expressed in tumours derived from ASPP2-deficient mice. Our results indicate that 
ASPP2 is important in limiting ΔNp63 expression in the differentiated epithelium, preventing 
cell proliferation in the upper layers of the skin. This is achieved by antagonising ΔNp63 
transcript and protein expression, resulting in a mutually exclusive expression pattern during 
differentiation of keratinocytes, as well as in epithelial cancer. Overall, our results indicate a 
possible mechanism by which p63 expression can be regulated in the skin, and provide a new 
model for the spontaneous formation of SCC. In contrast to p63, ASPP2 and Notch are co-
expressed in the differentiated layers of the squamous epithelium. Moreover, ASPP2 can 
interact with components of Notch nuclear transcriptional machinery, and can regulate 
communal target genes of both Notch and p73 proteins. 
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CHAPTER I: INTRODUCTION 
1.1  Tumourigenesis in brief 
The term tumourigenesis describes the process of transformation of normal cells into 
tumour cells, leading to a group of heterogeneous pathologies known as cancer. Transformed 
cells are characterized by the capacity of undergoing uncontrolled cell division and invading 
the surrounding tissues (Hanahan and Weinberg, 2011). Tumour progression is a multi-step 
process which begins with the acquisition of behavioural changes by a single cell, resulting in 
growth advantages compared to the normal cell population. These properties are transmitted to 
the descendent cells, which can undergo further changes and rapidly expand in size and 
number into the host tissue. Once the tumour is formed, some of the cancer cells can leave the 
tumour mass, invade the adjacent host tissue and reach the circulatory or lymphatic system, 
through which they can be transported in to new locations of the body and give rise to new 
tumour foci. These secondary tumours are called metastases and the presence of distant 
metastases is the main cause of mortality in cancer patients (Duffy, McGowan et al., 2008).  
The crucial changes in cell behaviour which characterize tumour cells have been 
classified in six main categories, considered the hallmarks of cancer cells, and include 1) self-
sufficiency in growth signals, 2) insensitivity to anti-growth signals, 3) limitless replicative 
potential, 4) evasion of apoptosis, 5) sustained angiogenesis and 6) tissue invasion and 
metastases (Hanahan and Weinberg, 2000). Recently, two additional hallmarks have been 
added to the list: the capacity of tumour cells to reprogram their energy metabolism and to 
avoid immune destruction (Hanahan and Weinberg, 2011). 
 
 
 
 
 
 
 
 
 
Figure 1 – The hallmarks of cancer - distinctive and complementary capabilities that enable tumor 
growth and metastatic dissemination (Hanahan and Weinberg, 2011). 
2 
 
The transition from a normal cell to a tumour phenotype is caused by cumulative genetic 
alterations. These alterations, ascribable to DNA-mutations, can be inherited through parental 
genes (familiar or hereditary cancer) or can arise de novo (non-inherited cancer). Gene 
mutations in cells result in tumour initiation when these events target genes which are crucially 
involved in controlling some of the cell behaviours described before. In general, these genes 
are divided in two classes: proto-oncogenes and tumour suppressor genes. The proto-
oncogenes act as crucial growth regulators in normal cell division and in cancer are subjected 
to activating mutations, becoming the so called “oncogenes”. On the contrary, the tumour 
suppressor genes, which normally act as negative growth regulators, are inactivated by 
mutations in cancer (Zhao and Epstein, 2011). Oncogenes are characterised by a dominant 
phenotype, defined as “gain of function”. This means that activating mutations in only one 
allele can result in alterations of cellular behaviour. Whereas, tumour suppressor genes usually 
require inactivating mutations targeting both alleles in order to produce phenotypic changes in 
the cell (“loss of function” phenotype) (Croce, 2008).  
1.2  The p53 family of proteins 
The p53 gene (TP53) is the most well-known and one of the best studied genes in the 
human genome and its popularity is primarily due its role as a major tumour suppressor 
(reviewed by Royds and Iacopetta, 2006). p53 was first discovered in 1979 as an interacting 
protein of the large T-antigen in SV40-transformed cells (DeLeo, Jay et al., 1979; Lane and 
Crawford, 1979; Linzer and Levine, 1979) and plays a pivotal role in controlling cell growth 
through its ability to induce cell cycle arrest or apoptosis in response to multiple stress signals 
(Bensaad and Vousden, 2007). 
p53 is the most frequently mutated gene in human cancer (Efeyan and Serrano, 2007) 
and it’s now recognised that in about 50% of all human tumours a key step for the 
development the malignancies is the direct inactivation of p53, via mutations, deletions or 
interactions with viral proteins. In the remaining half of the malignancies, p53 pathway is 
deregulated by inactivation of p53 activators and/or downstream targets or activation of its 
inhibitors. The importance for cancer cells to inactivate p53 comes from its pivotal role in 
blocking cell proliferation and preventing the generation of genetically altered cells. 
Fundamentally, p53 can integrate different stress signals, such as DNA damage or oncogenic 
stress, into a response which ranges from a transient cell-cycle arrest, to allow DNA repair, to a 
more definitive cell death via apoptosis or senescence (Lowe, 1999; Crighton, Wilkinson et al., 
2006). These functions make p53 probably the most important controller of genomic integrity 
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(Ryan, 2011), referred to as “guardian of the genome” (Lane, 1992). During the past decade 
numerous studies have further extended p53 functions, showing its involvement in processes 
such as autophagy, oxidative stress, regulation of metabolism, embryo implantation and 
angiogenesis (Teodoro, Parker et al., 2006; Hu, Feng et al., 2007). 
Almost twenty years after p53 was first described, two members of the p53 family of 
proteins, p63 and p73, were discovered (Kaghad, Bonnet et al., 1997; Yang, Kaghad et al., 
1998). These two homologues share high sequence identity with p53, which is reflected in 
some redundant functions in the gene expression regulation (Bergamaschi, Gasco et al., 2003). 
Despite all these similarities, p63 and p73 can be activated by distinct mechanisms and 
implicated in several p53-independent pathways, playing an important role in processes such 
development and differentiation (Levrero, De Laurenzi et al., 2000). 
 
1.2.1 Isoforms of the p53 family members 
The three family members (p53, p63 and p73) have a high degree of sequence similarity 
and domain conservation. The hallmark of their structure is the presence of three main 
domains: an acidic transactivation domain (TA) at the N-terminal, a core DNA-binding domain 
(DBD) and an oligomerisation domain at the C-terminal (OD) (Figure 2).  
The highest sequence identity among the three family members resides in the DBD 
domain (around 60%) suggesting p53, p63 and p73 can bind to the same DNA sequences and 
drive the transcription of the same set of genes. DBD is also the region where more than 97% 
of all the tumour-associated p53 mutations can be found (Stiewe, 2007). The oligomerisation 
domain of p53 can be post-translationally modified in different ways, including 
phosphorylation, methylation, ubiquitynation, resulting in a tight regulation of its function and 
stability. Unlike p53, both proteins p63 and p73 have an additional C-terminal tail containing a 
sterile alpha motif (SAM) domain, important for protein-protein interactions and often found in 
proteins involved in the regulation of development (Murray-Zmijewski et al., 2006) Moreover, 
all the three genes can encode two primary transcripts due to the presence of two distinct 
promoters in their sequence (P1 and P2). P1 promoter gives origin to full proteins, containing 
the TA, DBD and OD domains (referred to as FLp53, TAp63 and TAp73). Alternatively, when 
the transcription is initiated from the intronic P2 promoter, N-terminally truncated proteins are 
produced (referred to as Δ133p53, ΔNp63, ΔNp73).  
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Figure 2 – Structure of the p53 family of proteins (Stiewe, 2007). 
 
In both p53 and p73, additional ΔN variants can be generated by splicing events or 
alternative initiation of translation (Δ40p53, Δex2p73, Δex2/3p73 and ΔN’p73). Further 
complexity is added by the fact that the P1 and P2 transcripts can be spliced at the C-terminus. 
In total, concerning p53 and p63, for each of their TA and ΔN isoforms, three variants can be 
generated. For p73, a total of eight different isoforms have been identified from the P1 and P2 
promoters (Stiewe, 2007). 
 
1.2.2 The p53 family is a key mediator of the apoptotic response 
As p53 plays an important role in regulating cell proliferation and death, its activation 
has to be tightly controlled. The selectivity of p53 response is given by a combination of 
several factors, starting with the nature of the activating stress, which can be translated in 
different patterns of post-translational modifications on p53 protein, with consequent 
recruitment of characteristic binding partners and induction of a precise combination of target 
genes (Green and Kroemer, 2009). As a result of this multi-step process, p53 can facilitate the 
transient adaptation of cells to stressful conditions (summarized in Figure 3).  
The critical event during activation of p53 pathway is the stabilization and accumulation 
of its protein levels. In normal, unstressed conditions, p53 protein level is kept low mainly by 
the intervention of two crucial regulators: E3-ubiquitin ligase MDM2 and its related protein 
MDM4 (also called MDMX). MDM2 alone or in complex with MDM4 promotes 
ubiquitination of p53 and targets it to proteasomal degradation. Additionally, both MDM2 and 
MDM4 can inhibit p53 activity by binding it to the amino-terminal region and blocking p53 
transactivation domain (Linares, Hengstermann et al., 2003; Lavin and Gueven, 2006). 
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p53, as a transcription factor, can recognize consensus motifs which are present in the 
promoters of numerous genes (Green and Kroemer, 2009). Affinity for p53 binding can 
however vary among all the p53 binding sites. Thus, there are genes whose promoters contain 
high-affinity p53-binding sites, like p21, MDM2 and PUMA and others with low-affinity sites, 
as for example Bax (Braithwaite, Del Sal et al., 2006).  
  
 
 
 
 
 
 
 
 
 
Figure 3 – Simplistic diagram exemplifying the p53 response.  
In normal physiological conditions the levels of p53 are maintained low by the p53-MDM2 feedback loop. 
The release of MDM2 inhibition caused by various stress signals leads to an increase and stabilization of p53 
protein levels. The activity of p53 is also increased by post-translational modifications inducing various 
cellular responses. The nature of the activating stress dictates the severity of the response. Therefore mild 
stress can produce a temporary growth arrest, functional for dealing with the repair of the stress-inducing 
damage, while more severe stress can cause more dramatic and irreversible responses, such as senescence 
and apoptosis. 
 
1.2.3 The p53 family members in tumourigenesis, development and differentiation 
Differentiation is a physiological process which allows cells to switch off a proliferative 
program and, at the same time, preserving their cellular integrity and function. As the p53 
proteins are master regulators in mediating termination of cell proliferation, as well as 
induction of apoptosis, senescence and cell-cycle arrest, their role in differentiation and 
development has thoroughly been investigated. Recent evidences have supported the idea that 
p53/p63/p73 can be activated also by stimuli other than stress signals, regulating the 
expression of genes involved in diverse cellular processes like cell adhesion, motility and 
angiogenesis, suggesting they might be important to maintain normal cell function (Riley, 
Sontag et al., 2008). Despite their structural similarity, the p53 family of proteins appears to 
have unique roles in mouse and human development (see summary in Table 1).  
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Table 1 – Summary of the phenotypical characteristics of p53-, p73- and p63-null mice, underlining the 
differences in tumour predisposition and developmental defects. 
 
 
 
 
 
 
 
 
 
 
 
1.2.3.1 p53 
In human tumours, p53 is typically inactivated by gene deletion, mutation or 
overexpression of the p53-ubiquitin ligase MDM2 (Vousden and Lu, 2002). Mutations on p53 
gene can be found in half of all human tumours, with 95% of mutations occurring in the central 
region of the gene, which is responsible for sequence-specific DNA binding. Such p53 mutants 
can promote cancer onset by inactivation of the endogenous wild type p53, as well as through 
oncogenic gain-of-function activities (Brosh and Rotter, 2009). p53 ability to induce apoptosis 
still represents the key way by which p53 acts as a tumour suppressor (Cicalese, Bonizzi et al. 
2009). 
The observation that p53 negatively regulates the proliferation and survival of both adult 
and embryonic neural stem cells points to a role for p53 in controlling stem cell function 
(Armesilla-Diaz et al., 2009). Many studies have demonstrated that expression of p53 in 
undifferentiated cells can promote differentiation (Lin et al., 2005) suggesting that p53 not 
only controls cell renewal, but also cell fate.  
Studies conducted in p53-deficient mice have shown that p53 is required for normal 
embryonic development (Armstrong et al., 1995; Meletis et al., 2006). In utero exposure of 
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p53-null embryos to ionizing radiation as also shown that p53 has a role in reducing the rate of 
birth defects (Norimura, Nomoto et al., 1996). p53-mediated apoptosis in response to DNA 
damage is the mechanism causing the mortality in irradiated wild-type embryos, leading to 
their early death and preventing birth of individuals with congenital abnormalities. Other 
studies also shown that p53-null animals, both males and females, have reduced fertility. In 
females this is due to low levels of LIF, a protein important for embryo implantation, whose 
expression is normally induced by p53, while in males, the abnormality seems to be linked to 
an higher number of multinucleated giant cells found within the testis, believed to be a result of 
an inability to complete meiosis (Rotter, Schwartz et al., 1993; Hu, Feng et al., 2007). 
 
1.2.3.2 p63 and p73 
Although rarely mutated, p63 and p73 are abnormally expressed in human cancers 
(Muller, Schleithoff et al., 2006). The dominant-negative isoforms ΔNp63 and ΔNp73 are 
normally up-regulated in cancer. For instance, ΔNp63 was found frequently over-expressed in 
head and neck squamous cell carcinoma. Similarly, aberrant expression of ΔNp73 was detected 
in gliomas as well as colon carcinoma (Dominguez, Garcia et al., 2006). In contrast, TAp63 
and TAp73 tend to be lost or down-regulated in human tumours (Urist, Di Como et al., 2002). 
Additionally, mutant mice selectively depleted of the TAp73 isoform, but not ΔNp73, 
displayed a predisposition to tumour formation (Tomasini, Tsuchihara et al., 2008) suggesting 
TAp73 isoforms have tumour suppressor functions, as p53. 
Genetic experiments on mice have shown that p63 and p73 have a more profound effect 
on normal development than p53, and p63 deletion has the most striking effect. p63-/- mice 
have major developmental abnormalities such as the absence or truncation of limbs, 
craniofacial malformations and failure to develop skin and other epithelial tissues (Mills, 
Zheng et al., 1999; Candi et al., 2006). Functional studies have shown that p63 and its ΔN 
isoforms in particular are fundamental for the maintenance of the regenerative cell population 
and therefore the capacity of the epithelium to develop and differentiate (Candi et al., 2006).  
p73-/- mice have also developmental defects, but they survive postnatally and make it 
into adulthood. The range of abnormalities observed here clearly differs from those displayed 
by the p63-/- mouse, suggesting p73 has distinct developmental roles. p73-/- mice have 
neurological defects and additional in vitro studies showed that p73 expression (TAp73 
isoform) in neuroblastoma (undifferentiated neuronal cells) can induce neuronal differentiation 
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markers. The ΔNp73 isoform was also shown to play a role in developing neurons by opposing 
the apoptotic functions of TAp63 and p53 (Pozniak, Radinovic et al., 2000). Altogether these 
experiments confirmed p73 is deeply involved in neuronal differentiation, as p63 is for 
epithelial differentiation.  
 
1.3 The ASPP family of proteins: regulators of p53, p63 and p73 
1.3.1 Overview 
The ASPP (Apoptosis Stimulating Protein of p53) proteins have been identified and 
subsequently characterized as an important regulator of the p53 family members. Interactions 
with other proteins, as well as post-translational modifications are the ways by which p53, p63 
and p73 can differentiate among the variety of diverse cellular functions they have to 
accomplish. In particular, one of the common features of the p53-binding proteins appears to 
be in dictating whether p53 induces a cell cycle arrest or apoptosis. As the acronym ASPP 
suggests, the ASPP proteins specifically promote p53-dependent apoptosis, but not cell cycle 
arrest (Takahashi, Kobayashi et al. 2004). 
The ASPP family consists of three members, ASPP1, ASPP2 and iASPP (inhibitory 
ASPP). ASPP2 was the first of the family members to be characterized and it was originally 
identified as an interactor of p53 in a yeast two-hybrid screen of a transformed B cell cDNA 
library (Iwabuchi, Bartel et al., 1994). The newly identified p53-interacting protein was called 
53BP2, and consisted of only the last 529 amino acids of the full length ASPP2. The full-
length of ASPP2 however, was only recognised few years later as being 1128 amino acids long 
(Samuels-Lev, O'Connor et al., 2001). Currently we know that ASPP2 can exit as two splice 
variants derived from alternative splicing of exon3, called 53BP2S (BBP) or 53BP2L (ASPP2) 
which are 1005 and 1128 amino acids long respectively (Takahashi, Kobayashi et al. 2004). 
The second member of the ASPPs, named ASPP1, was initially identified as an N-
terminal truncated form of 948 amino acids, with high C-terminal homology to ASPP2 
(Nagase, Ishikawa et al., 1998). That original sequence was further extended to 1091 amino 
acids to obtain the complete full length ASPP1 (Samuels-Lev, O'Connor et al., 2001). Finally, 
iASPP was first reported as an inhibitor of RelA/p65 (RAI), with its size of 828 amino acids 
(Slee, Gillotin et al., 2004). The correspondent protein in Caenorhabditis elegans was found to 
be able to inhibit p53-dependent apoptosis, and since this organism does not express RelA/p65, 
the newly discovered protein was then called iASPP for its inhibitory function (Bergamaschi, 
Samuels et al., 2003). 
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1.3.2 Family members and structure 
ASPP1, ASPP2 and iASPP are encoded by three different genes positioned on three 
different chromosomes, respectively 14q32.33, 1q42.1 and 19q13.32-3. The family name 
ASPP also stands for Ankyrin repeats, SH3 domain and Proline-rich region containing-Protein, 
because of the presence of these three domains at the C-terminal of all the family members 
(Figure 4). The C-terminal is the most conserved region among the three proteins and the N-
terminal is only conserved in ASPP1 and ASPP2 and seems to have a role in determining the 
cellular localization of the two proteins (Yang, Hori et al. 1999). ASPP1 and ASPP2 are, in 
fact, mainly cytoplasmic, but when deprived of their N-terminal, the remaining C-terminal, 
which contains a nuclear localisation signal (Sachdev, Hoffmann et al., 1998), localises to the 
nucleus (Samuels-Lev et al., 2001). 
From an evolutionary point of view, iASPP is the most conserved member of the ASPP 
family, since an orthologue of the human iASPP can be found in C. elegans. ASPP1 and 
ASPP2, which can be found in mammals, are believed to be derived from iASPP through 
speciation (Bergamaschi, Samuels et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Structure of the ASPP family members. 
The ASPP family of protein consists of three family members: ASPP1, ASPP2 and iASPP. ASPP2 and 
iASPP are shown with their splice variants, respectively named BBP (Bcl-2 binding protein) and RAI 
(RelA/p65 inhibitor). The figure shows the length of the proteins and the common structural elements, 
highlighted with different colours Pro stands for proline-rich region, Ank for ankyrin repeats and SH3 for 
SH3 domain (Notari, 2011). 
 
1.3.3 Functions of the ASPP family 
The best characterised function of the ASPPs is their ability to regulate apoptosis acting 
on the p53 family of proteins. ASPP1 and ASPP2 are able to enhance the capacity of p53, p63 
and p73 to induce apoptosis, but not cell cycle arrest (Samuels-Lev, O'Connor et al., 2001; 
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Bergamaschi, Samuels et al., 2004). iASPP, the inhibitory member of the family, has opposite 
effects, thus allowing cell proliferation to occur (Bergamaschi, Samuels et al., 2003). 
ASPP1 and ASPP2 mode of action consists in selectively stimulating p53, p63 and p73 
binding to promoters of pro-apoptotic genes, such as Bax, PUMA and PIG3 (p53-induced gene 
3) resulting in their transactivation, but not to promoters of cell cycle arrest genes, such as 
CDKN1A or MDM2 (Samuels-Lev, O'Connor et al., 2001; Bergamaschi, Samuels et al., 
2004). ASPP1 and ASPP2 have been found in complex with p53 on promoters of pro-apoptotic 
genes by ChIP analysis (Samuels-Lev, O'Connor et al., 2001) and the crystal structure of the 
C-terminal of ASPP2 bound to the DNA core binding domain of p53 has also been solved 
(Gorina and Pavletich, 1996). The physical presence of the ASPPs in complex with p53, might 
thus induce conformational changes or recruitment of other factors, resulting in p53 binding to 
low-affinity sites (Ahn, Byeon et al., 2009). 
Additionally to p53/p63/p73, already mentioned, other ASPP binding partner have been 
identified, such as protein phosphatase 1 (PP1) (Helps, Barker et al., 1995), adenomatous 
polyposis coli-like (APCL) (Nakagawa, Koyama et al., 2000), YES-associated protein 1 
(YAP1) (Espanel and Sudol, 2001), amyloid-precursor protein-binding protein 1 (APP-BP1) 
(Chen, Liu et al., 2003), the hepatitis-C core protein (Cao, Hamada et al., 2004), SAM68 
(Thornton, Dalgleish et al., 2006), Par3 (Sottocornola, Royer et al., 2010) or Helicobacter 
pylori cytotoxin-associated gene A (CagA) (Buti, Spooner et al., 2011). Interestingly, the 
majority of these interactions are mediated by the Ankyrin repeats and SH3 domain, conserved 
among the three ASPPs. Considering the long list of interacting partners with their diverse 
cellular functions, it’s natural to think that the ASPPs can have multiple roles in the cell, other 
than inducing apoptosis, showing stimulating new prospective studies of this family.   
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Figure 5 – The ASPP proteins confer selectivity to the p53-stress response. 
Stress signals lead to stabilisation and activation of p53 protein, which can now direct different cellular 
responses by inducing the transcription of several different target genes. The same type of stress signals can 
also lead to accumulation of ASPP1/2, which can then interact with p53 family members and increase their 
ability to bind promoters specific for pro-apoptotic genes. iASPP, binding with p53 proteins acts instead as a 
trans-repressor of the same genes trans-activated by ASPP1/2, allowing cell proliferation to occur (Tordella, 
L., 2011). 
 
1.3.4 Role of ASPP family in tumourigenesis 
Given the great importance of the ASPP proteins in regulating the apoptotic process, it is 
logical to expect they can have a central role in tumourigenesis. Consistent with the fact that 
ASPP1/2 can induce apoptosis, while iASPP is an inhibitor of this process, several lines of 
evidence have shown that ASPP1/2 are tumour suppressors and iASPP is a proto-oncogene. 
One of the major contributions to support a role of ASPP2 in tumour suppression came from 
our laboratory, with a study on the ASPP2 knock-out mouse model (Vives, Su et al., 2006). 
ASPP2 heterozygous mice were viable but found to have higher incidence in tumour 
formation, both spontaneous and induced by ionising radiations when compared to wild-type 
mice. Consistent with the role of ASPP2 in regulating p53-mediated apoptosis, a combination 
of p53 and ASPP2 heterozygosity accelerated the onset of tumour development (Vives, Su et 
al., 2006). 
Another ASPP2 knock-out mouse has been recently generated by another laboratory and 
the subsequent tumour study showed overlapping results (Kampa, Acoba et al., 2009), 
confirming that ASPP2 is a tumour suppressor in vivo. The work published by our laboratory 
(Vives, Su et al., 2006), additionally showed that the spontaneous tumour formation in the 
ASPP2 heterozygous mice was not accompanied by a loss of heterozygosity, suggesting that 
ASPP2 behaves like a haploinsufficient tumour suppressor gene. This is supported by the fact 
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that ASPP2 has been found to be down-regulated in human tumours, but has not been found 
deleted or mutated (Liu, Lu et al., 2005).  
Finally, crystal structure analysis of the ASPPs bound with p53, added further insights 
into the relevance of these proteins in tumourigenesis. One important finding was that four 
amino acids in p53 DNA-binding domain involved in the interaction with ASPP2 (178His, 
181Arg, 243Met and 247Arg) are frequently mutated in human cancer (Gorina and Pavletich, 
1996). These analysis suggested that the disruption of ASPP2 binding to p53, with its 
consequent apoptotic-stimulatory effect, can be one way by which tumours inactivate p53 
tumour suppressor function. 
 
1.3.5 Role in normal development and differentiation 
Studies conducted in genetically modified mice showed that the ASPP proteins play a 
critical role in normal development. Additionally, all the individual ASPP-deficient mice 
displayed developmental defects largely not ascribable to abnormalities in p53/p63/p73 
pathways. The importance of the ASPPs in development is therefore due to their interaction 
with other identified binding partners, concerning functions that go beyond the regulation of 
apoptosis (Samuels-Lev, O'Connor et al., 2001). 
ASPP1 and ASPP2, in particular, are highly homologous at sequence level and have 
been shown to possess overlapping functions, at least in regarding p53 regulation (Samuels-
Lev, O'Connor et al., 2001; Bergamaschi, Samuels et al., 2004). iASPP knock-out mice 
generated in our laboratory, suffer from sudden death due to cardiomyopathy and display 
severe skin abnormalities, affecting the expression of several differentiation markers, as well 
as number and orientation of the hair follicles (Notari, Hu et al., 2011). Our group also showed 
that in the skin, iASPP cooperates with p63 for the maintenance of the homeostasis of the 
stratified epithelium (Notari, Hu et al., 2011). 
 
1.4 The Notch pathway 
1.4.1 Overview 
Notch signalling pathway is evolutionary conserved from Drosophila until human and it 
is involved in many fundamental cellular processes during development of the organism, as 
well as in self-renewing of adult tissues (Artavanis-Tsakonas, Rand et al., 1999; Schweisguth, 
2004). Processes that can be mediated by Notch pathways include promotion or suppression of 
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cell proliferation, cell death, acquisition of cell fates and activation of specific programs of 
differentiation. Accordingly, Notch proteins play a crucial role in differentiation and 
determination of cell fate. Their function however is critically context dependent, as in some 
cells/tissues they can promote differentiation (as in the skin) and in other sites Notch proteins 
are important for the maintenance of the proliferative potential of stem cell populations (as in 
the brain) (Artavanis-Tsakonas, Rand et al., 1999). Given the physiological importance of 
Notch signalling pathway, its loss or aberrant gain of function were found to be associated with 
several human disorders. Such disorders include developmental diseases (like Alagille 
syndrome, Tetralogy of Fallot, syndactyly, spondylcostal dysostosis, familiar aortic valve 
disease) (Gridley, 2003; Garg, Muth et al., 2005), diseases in adulthood (like CADASIL) 
(Louvi, Arboleda-Velasquez et al., 2006) and cancer (Weng, Ferrando et al., 2004; 
Ranganathan, Weaver et al., 2011). 
 
1.4.2 Role in development and differentiation 
Activation of Notch signalling results from the cell-cell contact thus is not surprising that 
many of its biological functions, such as proliferation and differentiation, are mediated by 
specific cells within a population, affecting neighboring cells with different properties.  
Notch is a pleiotropic pathway, whose final output is highly context dependent. The 
modulation of its activity appears therefore to be crucial. Regulators of Notch signalling are 
multiple and can intervene at different levels. Events that affect the activation of Notch 
pathway are posttranslational modifications, intracellular trafficking, epigenetic modifications 
and cross-talk with tissue-specific regulators (Bray, 2006). Post-translational modifications and 
intracellular trafficking in particular are important in regulating ligand and receptor 
availability, by limiting their expression spatially and temporally. This results in a modulation 
of ligand-receptor interactions and a tuning of Notch pathway activation. Several experimental 
evidences agreed in defining Notch as a factor important for the maintenance of the stem cell 
properties. Notch signalling, however, can have different effects in different organs and 
tissues. In the skin for example, Notch induces terminal differentiation. Here, Notch has an 
active role in promoting expression of differentiation markers, such as Keratin1 and 10 
(Rangarajan, Talora et al., 2001). 
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1.4.3 Role in tumourigenesis  
Despite the major role played by deregulated Notch pathway activity in solid tumours, 
few genetic alterations have been reported in Notch genes. This could be explained with the 
fact that in solid tumours Notch signalling is more dependent on the spatial context, such as the 
presence or absence of ligands, cellular inhibitors, cross-talk with other pathways, as the cells 
here are in touch with each other. Any abnormal variation in these factors can lead to 
inappropriate activation or inhibition of Notch pathway and cause tumour transformation 
(Miyamoto, Maitra et al., 2003; Santagata, Demichelis et al., 2004; Brennan, Momota et al., 
2009). 
In contrast with what was described so far, in tissues where Notch function is associated 
with induction of differentiation and growth suppression, Notch behaves as a tumour 
suppressor and inactivation of its activity can lead to tumour formation. This is the case of the 
skin, where Notch activity is physiologically important to promote terminal differentiation of 
the keratinocytes in various ways (Radtke and Raj, 2003). In vitro experiments conducted with 
keratinocytes, alongside with Notch defective mouse models, confirmed that the down-
regulation of Notch signalling promotes skin tumourigenesis (Koch and Radtke, 2007). 
Interestingly, in tumours in which Notch signalling is involved, its deregulation seems to 
be the consequence of the cross-talk with alerted pathways, which are physiologically 
important for the normal homeostasis of a given tissue. This suggests that Notch pathway has a 
broad fundamental role in differentiation and its outcome then acquires specific connotations 
in different tissues according to the interactions with environmental neighbouring factors. 
Alterations in such tissue-specific factors can directly affect Notch behaviour, providing the 
required contribution for tumour transformation (Ridgway, Zhang et al., 2006). 
 
1.5 Epithelial physiology 
1.5.1 Overview 
Epithelial tissues are located at the interface between the organism and the outside 
world, as simple monolayers that cover the digestive, respiratory, urinary and reproductive 
tracts, as glandular acini/alveolae (pancreas, salivary glands, breast gland, prostate, liver and 
others) or as multilayered tissues (for example, skin, mucosae of upper digestive and upper 
respiratory tracts, cornea). The largest epithelial tissue in the human body is the skin. The skin 
is composed by two compartments, an inner one called dermis and a more superficial one 
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called epidermis. Both dermis and epidermis are responsible for the formation of epidermal 
appendages, such as hair follicles, nails, sweat and mammary glands. The separation between 
dermis and epidermis is defined by a basement membrane (basal lamina) composed by proteins 
secreted by cells belonging to both epidermal and dermal compartment. The epidermis, as 
uppermost compartment of the skin, has the role of providing a physical and permeable barrier 
for the body, protecting the organism from dehydration, mechanical or bacterial harms. What 
makes the epidermis an efficient barrier is the nature of its composition: a multi-layered 
compartment. Keratinocyte cells are the “bricks” which compose such structure (Koster and 
Roop, 2004; Koster and Roop, 2007)  
The keratinocytes in the epidermis are organised as a stratified squamous epithelium. 
The stratification of the epidermis consists in a proliferative active basal layer, surmounted by 
progressively more differentiated supra-basal layers, named spinous, granular and cornified 
(Figure 6). New keratinocytes are originated by mitosis in the basal layer and then they move 
upwards throughout the layers, undergoing transcriptional and morphological changes during 
the transit. As the keratinocytes move up, they flatten and lose their proliferative potential, 
committing themselves to terminal differentiation by the expression of various forms of 
keratins (in a process known as keratinisation) until they eventually die when they reach the 
surface and they are sloughed off in process named desquamation. Lost dead cells are 
constantly replaced by new keratinocytes originated from asymmetric cell divisions of the stem 
cells resident the basal layer. These undifferentiated cells which have the ability of self-
renewal, play a fundamental role in skin homeostasis and repair (Blanpain and Fuchs, 2009). 
The overall epithelial stratification can be noticed by looking at the morphological diversity of 
each layer, which is associated to changes in the expression of keratins and others molecular 
markers (Koster and Roop, 2004).  
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Figure 6 – Model for epidermal stratification. 
The layers composing the multi-stratified squamous epithelium of the skin with their characteristic protein 
markers are shown. The names of the layers are abbreviated as: BM, basal membrane; BL, basal layer; SL, 
spinous layer; GL, granular layer; SC, stratum corneum. The calcium concentration, which goes increasing 
throughout the layers of the stratified epithelium, is an index of progression of cell differentiation.  
 
Keratins are intermediate filaments proteins, which exist in form of heteropolymers 
assembled with individual keratin proteins of two distinct types. For instance, keratin-14 (K14) 
is coupled with keratin-5 (K5), and keratin-10 (K10) with keratin-1 (K1). The proliferative 
basal layer of the epidermis is characterised by the expression of K14 and K5, while when cells 
enter the spinuos cell compartment they switch to expression of K10 and K1(Koster and Roop, 
2007). As the terminal differentiation of the keratinocytes proceed to the granular layer, protein 
kinase C (PKC) activity is important to repress the expression of the keratins 1 and 10. Ca2+ is 
a fundamental trigger in promoting epidermal differentiation and its concentration increases (as 
you go up) in the layers. Ca2+ in fact, not only regulates PKC activity, but also promotes cell-
cell contacts formation, which is a hallmark of differentiated keratinocytes (Koster and Roop, 
2007). 
 
1.5.2 Pathways involved in epithelial differentiation 
Whereas the morphological changes that occur during epidermal development have been 
extensively studied, the molecular mechanisms that govern this process still remain poorly 
understood. The main known pathways involved in skin differentiation and homeostasis are 
Notch and p63 pathways, whose importance has been underscored by the phenotypes of their 
mutant mice. The dynamic equilibrium existing in the skin between proliferating and 
terminally differentiated keratinocytes is in fact regulated by a reciprocal antagonistic activity 
in the upper versus lower layer, of p63 and Notch proteins (Koster and Roop, 2007) (Figure 7). 
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1.5.2.1 Role of Notch signaling in epithelial differentiation 
Notch complex is one of the main pathways involved in controlling differentiation in the 
skin. Its expression is restricted to the supra-basal differentiated layers of the squamous 
epithelium and absent from the proliferative basal layer. In keratinocytes, increased Notch 
activity causes exit from cell cycle and commitment to differentiation (Lowell et al., 2000; 
Rangarajan et al., 2001; Nickoloff et al., 2002), whereas down-modulation or loss of Notch 
function promotes carcinogenesis (Talora et al., 2002; Nicolas et al., 2003). 
Additionally, Notch can directly promote the expression of epithelial differentiation 
markers, such as keratin-1 and involucrin, and can down-regulate integrins expression 
(Rangarajan, Talora et al., 2001) (Figure 7). Other works showed the existence of a direct 
negative cross-talk between Notch and p63, which regulates the balance between proliferation 
and differentiation (Figure 7). A work by Nguyen and colleagues (2006) showed that Notch 
activation results in down-regulation of ΔNp63α (the main p63 isoform expressed in the skin) 
at mRNA and protein levels, both in vitro (human and mouse keratinocytes) and in vivo 
(mouse epidermis) (Nguyen, Lefort et al., 2006). Indirect evidences showed that mouse 
epidermis lacking of p63 present defective expression of Notch and, conversely, activation of 
p53 in human keratinocytes leads to Notch expression (Laurikkala, 2006; DiRenzo, 2003). 
Despite these findings, convincing evidences for a direct transcriptional regulation on Notch 
promoter by p53 and p63 are still missing. 
 
1.5.2.2 Role of p63 signaling in epithelial differentiation 
As the generation of Notch mutant mice revealed its importance in epidermis 
homeostasis, the same can be said for transgenic mice lacking of p63. Indeed, p63-/- mice have 
dramatic defects in the epidermis and all the epithelial appendages. The epidermal stratification 
does not take place in these mice, which are deprived of any skin stratification and die for 
dehydration early after birth (Mills et al., 1999; Yang, 1999). As previously mentioned, p63 
can exist in several forms, mainly distinguished as full-length TA and truncated-ΔN isoforms. 
The discovery of an additional trans-activation domain at the C-terminal of ΔNp63 showed 
that the ΔN isoforms do not just behave as dominant negative of the TA isoforms, but are also 
capable of inducing their own program of gene transcription (Candi, Dinsdale et al., 2007). 
To date, it is still unclear what specific contribution is given by the single isoforms, TA 
and ΔN, to the development of epithelial stratification. A work by Candi and co-workers 
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(2006) tried to address this problematic, by re-introducing single p63 isoforms into a p63-/- 
background and the result was a higher degree of epithelial rescue, suggesting TAp63 also 
contributes to epithelial stratification (Candi, Rufini et al., 2006). Its relatively late timing of 
expression during mouse development indicates that TAp63 probably just contributes in 
promoting the last step of differentiation in mature keratinocytes, while ΔNp63 is more active 
in the early stages of development, when it sustains proliferation of basal cells, leading to 
expansion of the epidermis. ΔNp63 is consistently expressed in the skin and it is strongly 
down-modulated with cell differentiation (Laurikkala, Mikkola et al., 2006). In the adult 
epithelia its general role is to promote proliferation of the keratinocytes, allowing stratification 
to occur in development and guaranteeing skin renewal and this isoform still represent the 
most abundant p63 isoform in the epidermis (99% versus 1% of TAp63) (Candi, 2007; Koster 
and Roop, 2007).  
At molecular level, this is achieved in several ways. For example, ΔNp63 can directly 
promote the expression of the basal keratins K5 and K14 (Candi, 2006; Romano, 2007) or the 
isoform can affect Notch signaling pathway at different levels, as counteracting Notch effect 
on the expression of some of its target genes or suppressing Hes1 and p21WAF1 expression, 
whilst promote integrin receptors (Nguyen, Lefort et al., 2006; Okuyama, Ogawa et al., 2007). 
Conversely, ΔNp63 can also synergise with Notch pathway during the early stages of 
differentiation, via a paracrine mechanism involving the expression of Jagged ligands, which 
leads to activation of Notch in neighbouring cells (Sasaki, Ishida et al., 2002). During 
development, ΔNp63 and Notch can also cooperate in promoting the expression of the early 
differentiation marker K1 (Nguyen, Lefort et al., 2006) (Figure 7). Additionally, p63 has been 
reported to be capable of binding directly the Notch promoter, although little evidence of any 
transcriptional effect has been reported so far in keratinocytes (Laurikkala, Mikkola et al., 
2006). 
Regarding its own gene expression, despite reports showing activating effects by p53, 
STAT3, Beta-catenin or ΔNp63 itself (Lanza, Marinari et al., 2006; Chu, Dai et al., 2008; 
Ruptier, De Gasperis et al., 2011), the transcriptional modulation of ΔNp63 is, to date, largely 
unknown. 
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Figure 7 – Interplay between Notch and p63 in regulating epithelial stratification. 
Cross-talk between p63 and Notch pathway, whose gradients of expression proceed in opposite direction 
throughout the stratified epithelium (see left side of the figure), is fundamental for maintaining the correct 
balance between self-renewing and terminal differentiated keratinocytes populations. BM, basal membrane; 
BL, basal layer; SL, spinous layer; GL, granular layer; SC, stratum corneum. (Tordella L, 2012). 
 
 
1.6 Epithelial cancer 
1.6.1 Overview 
Cancer is a disease mainly of epithelial cells; in fact, around 80% of human tumours 
derive from epithelial cells. Such tumours are called carcinomas and have the capability of 
invading surrounding tissues and organs and may metastasize, or spread, to lymph nodes and 
other sites. Carcinomas, like all neoplasias, are classified by their histopathological 
appearance. Adenocarcinoma and squamous cell carcinoma (SCC), two common descriptive 
terms for epithelial tumours, reflect the fact that these cells may have glandular or squamous 
cell appearances respectively. Mutations in the p53 gene have been detected in 50% of all 
human cancers and in almost all skin carcinomas (Basset-Seguin, Moles et al., 1994; 
Proweller, Tu et al., 2006). 
 
1.6.2 Squamous cell carcinoma 
Neoplasms originating from cutaneous epithelial cells, including adenocarcinoma, Basal 
Cell Carcinoma (BSC) and Squamous Cell Carcinoma (SCC), are the most common among the 
carcinomas. Cutaneous squamous cell carcinoma (cSCC) is the second most common human 
cancer with over 250,000 new cases annually in the US and is second in incidence only to 
basal cell carcinoma. cSCC typically manifests as a spectrum of progressively advanced 
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malignancies, ranging from a precursor actinic keratosis (AK) to squamous cell carcinoma 
(SCC) and finally metastatic SCC (Ratushny, Vladimir et al., 2012). 
Squamous cell carcinoma is a form of epithelial cancer that may occur in many different 
organs, including the skin, lips, mouth, oesophagus, urinary bladder, prostate, lungs, vagina, 
anus and cervix, and in these organs, it always arise from the keratinising cells of the 
squamous epithelium (Czarnecki, Staples et al., 1994; Bradford, Porcia T. et al., 2010).  
Unlike most BCCs, SCCs of the skin are associated with a risk of metastasis. In fact, of 
the three, SCC is the most malignant tumour type with the highest metastatic potential and 
refractory to treatment. SCCs can arise de novo or from precursor lesions (Salehi, Z. et al., 
2007), and it displays metastatic potential and furthermore, variants of SCC include 
noninvasive (well-differentiated) and invasive (high risk, poorly differentiated). Because it 
originates from differentiated layers of the epithelium, SCC retains features of the expression 
pattern characteristic of squamous cell differentiation, such as the presence of keratins 1 and 10 
(Wato, Kiyomi et al., 2012). 
 
1.6.2.1 Etiology 
The formation of SCC is based on genetic background, combined with environmental 
factors. The principal environmental risk factor for the SCC of the skin is the chronic exposure 
to ultraviolet (UV) light. When UV induced mutations occur in the “guardian of the genome” 
p53 gene, altering its capacity to induce apoptosis and cell-cycle arrest, there are high chances 
to develop BCC and SCC. Mutations in TPp53 are, in fact, detected in about 56% of BCC and 
90% of SCC of the skin (van Kranen, Westerman et al., 2005; Efeyan and Serrano, 2007). 
Experimental observations suggested that p53 inactivation may not be a critical rate-
limiting step in SCC formation, but mainly important for the progression of the malignancy 
and, additionally, for causing susceptibility in the case of the radiation-induced SCCs. 
Interestingly, what seems to be a primary natural cause for the formation of SCCs, is the 
aberrant over-expression of the p53-family member p63 (Hibi, Trink et al., 2000). Tumours 
with up-regulated p63 expression also showed frequent down-regulation of the Notch pathway 
(Lefort, Mandinova et al., 2007). 
 
1.6.2.1.1 Role of Notch signalling in SCC 
Consistent with its role in promoting terminal differentiation in the epidermis, the 
activity of Notch was found significantly reduced in SCC and BCC samples (Thelu, Rossio et 
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al., 2002; Lefort, Mandinova et al., 2007), making it a tumour suppressor protein in the skin. 
As mentioned earlier, mouse models carrying disruption in Notch signalling pathway led to 
epidermal abnormalities and spontaneous formations of SCC or BCC (Nicolas, Wolfer et al., 
2003). A model which has been proposed for Notch pathway downregulation during SCC 
involves the possibility that p53 could normally act as a positive modulator of Notch 
expression and, therefore, when its function gets compromised, by cancer-related mutations, 
then Notch would follow the same fate (Lefort, Mandinova et al., 2007). Another possibility is 
that Notch down-modulation is a consequence of p63 aberrant up-regulation, as p63 has been 
shown to have antagonistic effects towards Notch in the normal skin and its expression is 
frequently up-regulated in SCC. This hypothesis is supported by the observation that Notch 
expression appears to be down-regulated particularly in those SCCs where p63 is found up-
regulated (Lefort, Mandinova et al., 2007). 
 
1.6.2.1.2 Role of p63 signalling in SCC 
A common characteristic of almost all SCCs (about 90% of the cases) (Di Como, Urist et 
al., 2002) is the high level expression of p63, which is often due to gene amplification (Hibi, 
Trink et al., 2000; Yamaguchi, Wu et al. 2000). As for the normal squamous epithelium, the 
major isoform of p63 expressed in SCC is the ΔNp63α isoform, and a correlation between high 
levels of ΔNp63 and poor prognosis has been also established in SCC of the head and neck 
carcinomas (Choi, Batsakis et al., 2002). Mechanistically, the tumorigenic effect caused by the 
up-regulation of ΔNp63 expression seems to be linked with its inhibitory effects towards p53 
and p73 on their capacity to induce cell death via cell-cycle arrest, apoptosis and senescence 
(Levrero, De Laurenzi et al., 2000; Rocco, Leong et al., 2006). 
Another work has proposed that the ability of ΔNp63 to maintain the self-renewing 
capacity of normal keratinocytes as well as cancer cells is partly due the transcriptional 
repression of the Notch gene (via binding a p53-responsive element present on Notch 
promoter), establishing a link with the observation that high p63- expressing tumours have low 
Notch expression (Yugawa, Narisawa-Saito et al., 2010). 
Beyond the interaction with the other p53 family members and the effects derived by its 
own transcriptional properties, ΔNp63 up-regulation has also been shown to contribute to 
tumorigenesis via the activation of the beta-catenin signaling pathway, through reduction of its 
phosphorylation and consequent intra-nuclear accumulation (Patturajan, Nomoto et al., 2002). 
Nuclear beta-catenin is another factor which has been found often present in SCC and a recent 
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report suggests it can also promote the expression of ΔNp63, acting in a positive feedback loop 
(Ruptier, De Gasperis et al., 2011). 
Despite the amount of recent findings, the precise mechanism by which p63 mediates 
cell-survival and proliferation in SCC is still unclear and subject to investigation. Another 
important open question is what leads to altered expression of p63 in cancer cells, as putative 
binding sites for several transcriptional factors have been identified, but only modest effects in 
terms of activation have been reported at date, both in vitro and in vivo. 
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Aim of the work 
The goal of this work was to identify and characterise new functions for the protein 
ASPP2 in the skin epithelium. The main objectives were: 
1. To evaluate whether ASPP2 positively or negatively regulates the expression of p63 in 
squamous epithelium and which pattern of expression and location these two proteins have in 
the skin. 
2. To characterise the behaviour of both proteins at transcriptional level in the presence of 
different factors and in different cell lines. We wanted to elucidate whether ASPP2 can 
regulate the transcription of ΔNp63 promoter on genes involved in epithelial differentiation.  
3. To test for a putative relationship between ASPP2 and Notch, another protein 
important during the differentiation of the epidermis.  
4. Lastly, we wanted to study Notch and p73 target genes regulated by ASPP2, as ASPP2 
is a common activator of p73 and p63. In central nervous system one of the key factors 
determining cell fate determining factors is p73 but, in the epidermis, this role is taken p63 that 
determines cell fate, so it is emerging that many Notch target genes are also p73/p63 targets.  
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CHAPTER II: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Reagents   
All chemicals, unless otherwise stated, were obtained from Sigma (Sigma, MO, USA) or BDH 
Chemicals (UK). Autoradiography films (Hyperfilm) and ECL (Enhanced Chemi-
Luminescence) reagents were purchased from Amersham Pharmacia Biotech (UK). 
Nitrocellulose membrane was purchased from Whatman, Germany. All tissue culture dishes 
and flasks were obtained from BD (Becton, Dickinson and Company, NJ USA). The 
Luciferase Assay System Kit was purchased from Promega (WI, USA) and the QIAGEN 
Plasmid Maxi kit was purchased from Qiagen (UK).  
 
Ammonium Persulphate (APS) 
10% (w/v) stock solution was prepared in water and stored at -20˚C in single-use aliquots.  
 
Ampicillin Stock 
0.5g of the antibiotic was dissolved in 10 ml sterile distilled water, creating a 50mg/ml 
solution. This was stored at -20˚C as aliquots. 
 
Blocking Solution 
10% (w/v) fat-free milk (Marvel, UK) was prepared in 1X TBS-T. 
 
COmpleteTM protease inhibitor cocktail 
One COmpleteTM protease inhibitor (Boehringer Mannheim, Germany) tablet was dissolved in 
2.0ml of sterilised distilled water as a 25x stock solution that is stable at -20 ˚C for 12 weeks.  
 
DAPI staining solution 
Powdered DAPI was dissolved at 1mg/ml and stored at -20°C in aliquots. 
 
EDTA Solution 
A 0.5M C10H14N2O8Na2.2H2O (EDTA) stock solution was made by dissolving 186 g of EDTA 
in 700ml distilled water. The pH was adjusted to pH 8.0 with NaOH and the volume made up 
to 1l with distilled water.  
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Freezing Medium 
90% (v/v) Fetal Calf Serum (FBS) 
10% (v/v) DMSO 
Made fresh every time. 
 
LB medium 
LB powder was dissolved as recommended by the manufacturer’s instruction, autoclaved and 
stored at RT. 
 
Lipotransfection reagents 
Lipotransfections were performed with Fugene 6 (Roche) or Lipofectamine®2000 (Invitrogen), 
following the manufacturer’s recommendations or as otherwise stated. 
 
Luciferase Assay System  
This assay system was purchased from Promega (WI, USA). The solutions were made up 
according to the manufacturer’s directions and stored at -20˚C. All solutions were allowed to 
equilibrate to room temperature before use. 
 
NETN buffer 
50mM   Tris pH 8.0 
150mM  NaCl 
1mM   EDTA 
1% (v/v)  NP40 
Stored at RT. Complete protease inhibitors were added before use. 
 
Phosphate Buffered Saline (PBS) 
12.5 mM NaCl 
1      mM Sodium dihydrogen phosphate, NaH2PO4 
1.6   mM Disodium dihydrogen phosphate, Na2HPO4 
The pH was adjusted to 7.0 and autoclaved.  
 
Protein Molecular weight markers 
Pre-stained protein markers were purchased from New England Biolabs (UK) and were used as 
a size standard for SDS-polyacrylamide gel electrophoresis. 
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Qiagen Elution Buffer 
1.25   M  NaCl 
50   mM Tris-HCl pH8.5 
15%  Isopropanol 
 
Qiagen Equilibration Buffer 
750 mM NaCl 
50   mM MOPS pH 7.0 
15 %   Isopropanol 
0.15%  Triton® X-100 
 
Qiagen Wash Buffer 
1   M  NaCl 
50 mM  MOPS pH 7.0 
15%  Isopropanol 
 
RIPA Lysis Buffer  
150    mM NaCl 
1%    (v/v) NP40 (or equivalent) 
0.1% (w/v)  SDS 
50      mM Tris-HCl (pH 8.0) 
1/25  COmpleteTM Protein Inhibitor Cocktail  
 
SDS Solution 
A 10% (w/v) solution of sodium dodecyl sulphate (SDS) was dissolved in water and stored at 
room temperature. 
 
2X SDS-PAGE loading dye 
100mM            Tris-HCl (pH 6.8) 
4% (w/v) SDS 
20% (v/v) Glycerol 
0.2% (w/v) Bromophenol Blue  
Before use, 5% (v/v) β-Mercaptoethanol was added fresh to the 2X SDS-PAGE loading dye. 
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10x SDS-PAGE Running Buffer 
720 g  Glycine 
150 g  Tris 
50 g  SDS 
Final volume adjusted to 5l with distilled water 
 
10x SDS-PAGE Transfer Buffer 
725 g  Glycine 
145 g  Tris 
Final volume adjusted to 5l with distilled water. The buffer was then used with 20% ethanol as 
1X solution. 
  
TO-PRO  
The nuclear dye was purchased as liquid from Invitrogen and stored at -20°C in aliquots. 
 
Tris Stock solutions 
Tris base was dissolved in water to provide 0.5M, 1M and 1.5M solutions which were pH 
adjusted with concentrated HCl. 
 
10x Tris Buffered Saline Tween (TBS-T) 
121g  Tris base 
36.53g   NaCl 
250ml     Tween-20  
pH adjusted to 7.6 with around 60ml HCl in a total volume of 5 litres. Used at 1x 
concentration. 
 
Triton® X-100 
A 20% (v/v) stock solution in PBS was made and stored at room temperature. 
 
Water 
Nanopure water (Type I) generated from the MilliQ water system was used for all procedures. 
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2.1.2 SDS-polyacrylamide Gels  
      Table 2 – List of reagents used to prepare resolving and stacking gels at different concentrations.  
 
 Resolving Gels Stacking 
 6% 8% 10% 12% 4 % 
Acryl/Bis 2 ml 2.7 ml 3.3 ml 4.0 ml 1.3 ml 
1.5 M Tris-HCl pH 8.8 2.5 ml 2.5 ml 2.5 ml 2.5 ml -- 
1.0 M Tris-HCl pH 6.8 -- -- -- -- 2.5 ml 
10% SDS 100 µl 100 µl 100 µl 100 µl 100 µl 
10% APS 100 µl 100 µl 100 µl 100 µl 50 µl 
TEMED 10 µl 8 µl 5 µl 5 µl 10 µl 
Distilled Water 5.3 ml 4.6 ml 4.0 ml 3.3 ml 6.1 ml 
Total volume 10 ml 10 ml 10 ml 10 ml 10 ml 
  
All resolving and stacking gels were prepared using 30% acrylamide/bis-acrylamide 
(Acryl/Bis) 29:1 (NBL, UK or BioRad, UK). Values given are per 10ml of gel required. 
Abbreviations: Ammonium Persulphate (APS); N,N,N’,N’,-tetramethy-ethylenediamine (TEMED), 
Tris (Tris(hydroxymethyl) aminomethane), sodium dodecyl sulphate (SDS). 
 
2.1.3 Antibodies 
2.1.3.1 Primary antibodies 
 
Table 3 – List of primary antibodies. 
 
antigen Ab name host/type source applications 
Actin C-2 mouse mAb Santa Cruz (sc-8432) WB (1:1000) 
ASPP2 S-32 rabbit pAb serum 
ICC/IF (1:100), WB 
(1:1000) 
ASPP2 DX54.10 mouse mAb ascite 
IHC (1:400), ICC/IF 
(1:100), WB (1:1000), 
IP 
Envoplakin M-20 goat pAb Santa Cruz (sc-16751) WB (1:1000) 
iASPP LX49.3 mouse mAb ascite 
ICC/IF (1:200), WB 
(1:1000) 
Keratin-1 AE1 mouse mAb Abcam (ab9286) IHC (1:400) 
Keratin-14 PRB-155P-100 rabbit pAb Covance IHC (1:400) 
Ku80 Ab-2 mouse mAb Thermo Fisher ICC/IF (1:200) 
myc-tag 9E10 mouse mAb ascite WB (1:1000) 
Notch1 C-20 rabbit pAb Santa Cruz (sc-6014- IHC (1:400), WB 
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R) (1:1000) 
p53 DO-1 mouse mAb Santa Cruz (sc-126) ICC/IF (1:200) 
p63 4A4 mouse mAb Santa Cruz (sc-8431) 
IHC and ICC/IF 
(1:400), WB (1:1000) 
p63 - rabbit pAb Abcam (ab53039) 
IHC and ICC/IF 
(1:400) 
V5-tag - rabbit pAb Abcam (ab9116) 
ICC/IF (1:400), WB 
(1:1000) 
Vimentin RV202 mouse mAb Abcam (ab8978) IHC (1:400) 
β-tubulin TUB 2.1 mouse mAb Abcam (11308) WB (1:1000) 
 
 
2.1.3.2 Secondary antibodies 
 
 
Table 4 – List of secondary antibodies. 
 
 
Abbreviations – antibody (Ab), monoclonal antibody (mAb), polyclonal antibody (pAb), horse-radish 
peroxidase (HRP), Immunohistochemistry (IHC), Immunocytochemistry/Immunofluorescence 
(ICC/IF), Western blot (WB), Immunoprecipitation (IP), Chromatin Immunoprecipitation (ChIP).  
 
 
 
 
 
 
Ab name host/type source applications 
Alexa Fluor® 488 F(ab’)2 fragment anti-rabbit IgG goat Invitrogen IF (1:400) 
Alexa Fluor® 488 F(ab’)2 fragment anti-mouse IgG goat Invitrogen IF (1:400) 
Alexa Fluor® 546 F(ab’)2 fragment anti-rabbit IgG goat Invitrogen IF (1:400) 
Alexa Fluor® 546 F(ab’)2 fragment anti-mouse IgG goat Invitrogen IF (1:400) 
Alexa Fluor® 647, 488 Anti-Mouse IgG (H+L) Donkey Invitrogen IF (1:400) 
Alexa Fluor® 647, 488 Anti-Rabbit IgG (H+L) Donkey Invitrogen IF (1:400) 
Anti-Mouse Immunoglobulins/HRP rabbit Dako IHC (1:250), WB (1:2000) 
Anti-Rabbit Immunoglobulins/HRP swine Dako  IHC (1:250), WB (1:2000) 
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2.1.4 Plasmids 
Table 5 – List of plasmids used in Luciferase Assay System. 
name vector information tag source 
ASPP2 pcDNA3.1 human ASPP2 V5 and His Dr S. Llanos, UCL, UK 
iASPP pcDNA3.1 human iASPP V5 and His Dr S.Llanos, UCL, UK 
Control plasmid pcDNA3.1 empty vector V5 and His Invitrogen 
Notch intracellular 
domain (ID) 
pcDNA3.1 human Notch ID Myc 
Dr T. Kadesh, Universityof 
Pennsylvania, USA 
Renilla pRL-TK  - Promega 
EVPL-Luciferase pGL3 
envoplakin promoter 
cloned 5’ to the firefly 
luciferase gene 
- 
Prof G. Melino, University 
of 
Leicester, UK 
K14-Luciferase pGL3 
envoplakin promoter 
cloned 5’ to the firefly 
luciferase gene 
- 
Prof G. Melino, University 
of 
Leicester, UK 
ΔNp63α pcDNA3 human ΔNp63α - 
Dr I. Shachar, Weizmann 
Institute of Science, 
Rehovot, Israel 
K10-Luciferase pGL3 
K10 promoter 
cloned 5’ to the firefly 
luciferase gene 
- 
Dr B. Andersen, 
Laboratory 
University of California, 
USA 
ΔNp63-Luciferase pGL3 
ΔNp63 promoter 
cloned 5’ to the firefly 
luciferase gene 
- 
Dr E. Candi, University of 
Tor Vergata, Italy 
Hey2-luciferase pGL3 
Hey2 promoter 
cloned 5’ to the firefly 
luciferase gene 
- 
Prof M. Gessler,   
Biozentrum, Germany 
 
2.1.5 Cell lines 
Table 6 – List of established cell lines used in this work. 
name tissue/type source 
H1299 human lung carcinoma ATCC 
HSC3 Human squamous cell carcinoma of the head and neck Dr S. Feller, University of 
Oxford, UK 
SCC-4 Human squamous cell carcinoma of the head and neck Dr S. Feller, University of 
Oxford, UK 
CAL-27 Human squamous cell carcinoma of the head and neck Dr S. Feller, University of 
Oxford, UK 
OSC-20 Human squamous cell carcinoma of the head and neck Dr S. Feller, University of 
Oxford, UK 
Saos-2 Human osteosarcoma ATCC 
 
Abbreviations – American Type Culture Collection (ATCC) 
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2.2 Methods       
2.2.1 Tissue culture 
Basic Media 
Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased from Gibco-BRL, UK and 
stored at 4°C. Eagle’s Minimum Essential Medium (EMEM) with Earlie’s balanced salts 
solution (EBSS), non-essential amino acids and L-Glutamine without Calcium Chloride was 
purchased from Lonza, MD USA. 
 
Media supplements 
Fetal calf serum (FCS) was purchased from PAA Laboratories and tested for its ability to 
support growth of various cell lines. It was heat inactivated for 30 minutes at 55°C and stored 
at -20°C in 50 ml aliquots.  
L-Glutamine was purchased from Gibco-BRL at a 200mM concentration stored at -20°C and 
used at a final concentration of 2 mM. 
Penicillin/Streptomycin was purchased from Gibco-BRL at 10,000 units/ml stored at -20°C 
and used at a final concentration of 200 units/ml. 
 
Maintaining cell lines 
All cell lines were cultured in Complete Medium (DMEM) supplemented with L-Glutamine, 
penicillin/streptomycin and 10% (v/v) foetal calf serum in flasks or dishes (Falcon) maintained 
in a Heraeus incubator at 37°C in the presence of 10% CO2. Medium was changed every 3-5 
days depending on the cell lines. On reaching confluence, the cells were washed once with 1X 
PBS and incubated with 2-4ml pre-warmed Trypsin-EDTA (Gibco-BRL) at 37°C until the 
cells detached from the flasks or dishes. Trypsin was inhibited by addition of an appropriate 
volume of fresh growth medium and this culture was then seeded on to fresh flasks or dishes at 
the desired density. 
Undifferentiated primary keratinocytes were cultured in Eagle’s Minimum Essential Medium 
(EMEM) without calcium chloride, supplemented with 0.05mM CaCl2, L-Glutamine and 8% 
CaCl2 chelate fetal calf serum (lab stock). When needed undifferentiated primary keratinocytes 
were differentiated by the addition of CaCl2 in the medium to a final concentration of 1.2mM 
(Hennings, Holbrook et al., 1980). 
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Freezing/thawing of cells 
Cells were grown to about 80% confluency and collected by trypsinization (as described 
above). The cell pellet was resuspended in the appropriate amount of freezing medium and 
aliquoted in cryovials (Corning). The vials were then labelled and cooled at the rate of 1˚C per 
minute in a Nalgen Cryo 1 ˚C freezing container or in a tissue-insulated polystyrene box when 
placed in a -80˚ C freezer (New Brunswick Scientific) for at least 24 hr before being 
transferred to liquid nitrogen tank for long term storage. 
To thaw cells from liquid nitrogen stock, vials were placed in the 37 ˚C water bath for 2 
minutes and then transferred to a 6cm or 10cm dish with the appropriate pre-warmed fresh 
growth medium and kept in the 37 C incubator overnight for recovery. 
 
2.2.2 DNA techniques 
Bacterial strains and culture 
Chemically competent Escherichia coli strain alpha-select™ silver efficiency (Bioline) was 
used as a host for plasmid DNA. Bacteria were cultured in LB medium containing the 
appropriate antibiotic (100g/ml ampicillin) in flasks shaking at 37 °C. 
 
Transformation 
Competent cells were thawed on ice, followed by addition of the desired plasmid DNA to a 
vial of competent cells. The mixture was incubated on ice for 30 minutes. The bacteria were 
subjected to heat shock for 30 seconds at 42 °C in a water bath followed by incubation on ice 
for another 2 minutes. 500l of LB-medium without antibiotics was added to the tube and the 
sample left to shake at 37 ºC for 1 hour before plating on LB-agar plates with an appropriate 
antibiotic. Plates were then incubated at 37 ºC overnight. 
 
Large scale preparation of plasmid DNA (maxi-prep) 
A single bacterial colony was used to inoculate 5ml of LB/antibiotic medium in a sterile test 
tube, and shaken at 37 ºC for 4 hours. The resulting bacterial suspension was used to inoculate 
a 250ml flask of LB/antibiotic medium and shaken for a further 16 hours at 37 ºC.  The cells 
were centrifuged at 6,000g for 15 minutes at 4 ºC (Sorvall RC 5C Plus, rotor SLA-3000). The 
large scale DNA preparation was carried out according to Qiagen Qiafilter Maxi DNA kit 
protocol. 
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2.2.3 Protein manipulation 
Sample preparation 
Cells grown in monolayers were washed three times with 1X PBS and lysed in appropriate 
lysis buffer (100-500l per 10cm dish). The cells were scraped with a sterile disposable cell 
scraper (Greiner), transferred to eppendorf tubes and left on ice for 30 minutes, vortexing 
occasionally. The mixture was cleared by centrifugation at 15,000 g, at 4 ºC for 10 minutes. 
The resulting lysate was removed to a fresh eppendorf tube and the cell debris discarded. 
 
Protein concentration determination 
The protein concentrations of cell extracts were determined using the BioRad protein assay 
reagent system. 1µl of cell lysate was mixed with 200µl of 1x BioRad assay reagent and then 
measured at 595nm in the spectrophotometer (Anthos Labtech instrument). All samples were 
measured in duplicate and the absorbance was compared against a standard curve made at the 
same time from known concentrations of bovine serum albumin (BSA; Sigma-Aldrich) in the 
same solutions, using the same method. 
 
Preparation of SDS-polyacrylamide gels 
All plates were washed with water and detergent, dried and assembled in the casting trays 
(Pharmacia BioTech, UK). The acrylamide content of the gels varied between 6%-12% 
depending on the size of the protein of interest. The acrylamide gels were overlaid with 70% 
isopropanol solution and left to polymerise. After polymerisation, the isopropanol was 
removed and a 4% stacking gel was set with the appropriate number and size wells.  
 
SDS-polyacrylamide gel electrophoresis (PAGE) 
Known concentrations of protein were mixed with appropriate volumes of 5x SDS-PAGE 
Sample Loading Buffer and boiled for 5 min. Cell lysates and protein molecular weight marker 
in sample buffer were loaded onto SDS-polyacrylamide gels in a 1x SDS-PAGE running 
buffer and the proteins electrophoresed at a constant voltage of 100-250V. Equal amounts of 
protein were loaded in each lane as determined by the BioRad assay system, unless otherwise 
stated. 
 
 
 
35 
 
Immunoblotting 
After the samples were separated through the gel, the gel was transferred to a wet transfer unit 
containing 1x SDS-PAGE transfer buffer. The proteins were then electrophoretically 
transferred onto nitrocellulose membrane (Schleicher and Schull, Germany) for 1-3 hours at a 
constant voltage of 65V, or 20V overnight, in a Hoefer Transphor Electrophoresis unit. The 
membrane was then stained with Ponceau S solution to determine the success of the transfer of 
proteins and equal loading of the lanes. The membranes were then washed in water and 
incubated in 5% fat-free milk (Marvel, UK) in 1x TBS-Tween at room temperature for 40-60 
minutes. Primary antibody was added at the recommended concentrations, diluted in TBS-
Tween plus 5% milk, for 3h at RT or overnight at 4ºC. After three 15min washes in 1x TBS-
Tween, the secondary antibody was added for 1h at RT (1:2000). Membranes were washed 
another three times for 15min in TBS-Tween. The results were visualized by enhanced 
chemoluminescent detection, ECL (Amersham Biosciences) using X-ray films (Fujifilm). If 
probing with another primary antibody was required, the gels were either immediately 
reprobed or incubated with stripping buffer for 30 min at 55°C and reblocked in 5% milk, 
before incubation with the new primary antibody.   
 
2.2.4 Cell-based assays 
Cell transfection 
Lipofectamine 2000 (Invitrogen) was used as DNA-lipid carrier and used according to the 
manufacturer’s protocol. 
 
In vivo Transcription assays 
Cells were seeded at about 80% confluence in wells of a 24-well plate and transfected 24h later 
using Lipofectamine2000 with the various expression plasmids, including a luciferase reporter 
plasmid. Twenty-four hours after transfection, cells were washed twice with PBS, lysed in 100 
µl 1x Reporter Lysis Buffer, collected with a pipette and put in eppendorf tubes. The lysate 
was left on ice for 15 minutes before spinning them at 15,000 g for 5 minutes. 20 µl of 
supernatant was then placed in a wash tube (Sarstedt, Germany) and its luciferase activity 
measured in an automated Luminometer (AutoLumat LB 953, EG&G, Berthold) using the the 
Dual-luciferase® reporter assay system (Promega, USA). The mean values were calculated 
from at least two independent experiments. 
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Histology and immunohistochemistry 
Tissues were fixed in 10% buffered formalin overnight and then dehydrated in an ethanol 
series, cleared in histoclear and embedded in paraffin wax. Sections were cut at 4µm thickness 
and either stained with hematoxylin and eosin or processed for immunostaining. Rehydrated 
paraffin-embedded sections were microwaved in 10mM sodium citrate buffer, pH 6, incubated 
in 3% hydrogen peroxide in methanol, washed in PBS and after blocking with 5% goat (or 
donkey) serum in PBS for 1h at RT, sections were incubated overnight at 4°C with the primary 
antibody diluted in blocking solution. Next, sections were incubated with either biotinylated or 
Alexa Fluor® (1:400, Molecular Probes) labelled secondary antibodies, always in blocking 
solution, for 30 minutes at room temperature. Bright light staining was visualised using the 
peroxide substrate solution DAB (diaminobenzidine, Vector). Primary antibodies used and 
relative concentrations are listed in Table 3.  
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Mesenchymal marker 
vimentin 
Squamous epithelial markers 
Keratin-14, Keratin-1, p63 
Control  
CHAPTER III: RESULTS  
3.1 The tumours developed by the ASPP2 mutant mice are poorly 
differentiated SCC 
 To evaluate the role of ASPP2 in skin tumour formation we performed morphological 
analysis of epithelial tumours. We found that tumour cells from ASPP2 Δexon3 homozygous 
and heterozygous mice did not express vimentin, according to the immunohistological results. 
On the contrary, we found high levels of keratin-14 (K14) and keratin-1 (K1).  Tumours from 
the ASPP2 mutant mice (Δexon3) also revealed marked expression of nuclear p63 (Figure 8). 
Histological analysis of the epithelial tumours spontaneously formed in the ASPP2 mutant 
mice revealed them to be poorly differentiated, characterized by elevated expression of K14, 
K1 and nuclear p63.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Immunostaining of the epithelial tumours. a) Control result, hematoxylin and eosin staining of 
lung metastases. Detection of b) vimentin (negative), c) Keratin-14 (positive), d) Keratin-1 (positive) and e) 
p63 (positive). The last three are all markers for SCC. Scale bars: 100 μm in a) and 50 μm in b) – e).  
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3.2 Cooperation between ASPP2 and p53 in tumour suppression  
3.2.1 p63 expression is up-regulated in ASPP2-deficient cells and both negatively 
correlate in squamous epithelium 
In order to verify whether ASPP2 could be a significant factor in epithelial homeostasis, 
we compared ASPP2 expression with that of p63 expression in human stratified epithelium. 
Immunofluorescence analysis showed high levels of ASPP2 expression in the adult human 
skin epithelium. Interestingly, the pattern of expression of ASPP2 was mutually exclusive with 
the one of p63, as no expression of ASPP2 was detected in the basal layer of the skin, where 
p63 is highly abundant (Figure 9). 
 
 
 
 
 
 
 
 
 
Figure 9 – ASPP2 and p63 mutual exclusive pattern of expression in skin tissue. Double staining of 
human squamous epithelium of the skin with anti-ASPP2 and anti-p63 antibodies showing that ASPP2 and 
p63 have an almost mutually exclusive pattern of expression. Scale bar: 50 μm. 
 
To test whether ASPP2 might be a factor involved in the differentiation of the squamous 
epithelium, we analysed the pattern of ASPP2 expression during cell differentiation in primary 
mouse keratinocytes by Western Blotting. Pluripotent keratinocytes isolated from 3 days old 
wild type mice were allowed to grow in culture in a Ca2+-free medium, which permits 
proliferation while inhibiting terminal differentiation, resembling the properties of the 
keratinocytes present in the basal layer of the skin. After two days, Ca2+ was added in the cell 
growth medium, allowing cells to establish cell-cell contacts, to withdraw from the cell-cycle 
and differentiate, mimicking the physiological process of cell stratification taking place in the 
squamous epithelium. As a control for the successful outcome of the process of cell-
differentiation, the presences of envoplakin, a protein induced with terminal differentiation 
(Karashima, T. and Watt FM., 2002) as well as the disappearance of p63, marker of cell 
pluripotency (Davydova, DA et al., 2009) were evaluated. Interestingly, ASPP2 expression 
was found to be up-regulated during differentiation, alongside with envoplakin and 
concomitant with p63 down-regulation (Figure 10). 
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Figure 10 – Evaluation of ASPP2 levels of expression compared to other skin markers during 
differentiation of mouse primary keratinocytes. Lysates were prepared from cells cultured in absence of 
calcium (Ca
2+
) in the medium and then after one and five days upon the addition of Ca
2+
. Immunoblotting 
was performed using antibodies anti-envoplakin (EVPL), anti-ASPP2, anti-p63 and anti-βtubulin (loading 
control).  
 
The following hypothesis could explain why when ASPP2 expression is compromised, 
as it is in the ASPP2-deficient mice, we observed over-expression of p63 in the skin and 
spontaneous formation of SCCs (Figure 11). The absence of ASPP2 expression from the upper 
strata would release the inhibition on p63, which could be expressed upwards throughout all 
the epithelium and lead to SCC formation, as observed in the ASPP2 deficient mice. 
 
 
 
 
 
 
 
 
 
Figure 11 – Model of ASPP2 importance in preventing p63 expression and therefore suppress tumour 
formation. BM, basal membrane; BL, basal layer; SL, spinous layer; GL, granular layer; SC, stratum 
corneum.  
 
3.2.2 ASPP2 regulates p63 expression at transcriptional level 
All previous experiments were performed in adult tissue, and so afterwards we 
investigated how ASPP2 can regulate p63 at transcriptional level, i.e., understand how ASPP2 
controls the regulation of transcription of p63 factor. In the first experiment we tested whether 
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ASPP2 could repress directly ΔNp63 expression, doing a luciferase transactivation assay in 
H1299 human cell line. Transcriptional activity of ΔNp63 promoter was measured transfecting 
ΔNp63 and ASPP2-V5 expression vectors (V5 is an epitope recognized by the mouse 
monoclonal antibody V5, a specific tag for exogenous ASPP2) into H1299 cells. Luciferase 
activity was analysed from cell lysates 24h after transfection, and normalised for the signal 
from renilla and this is expressed as fold induction. Using the same lysates, the transfection 
was confirmed by Western blotting analysis, using antibodies anti-V5 (ASPP2), anti-p63 and 
anti-actin (loading control). In this analysis, we observed that ΔNp63α (the main p63 isoform 
expressed in the skin) is capable of activating the ΔNp63 promoter and ASPP2 shows no effect 
when co-transfected in combination with ΔNp63α or p53 (Figure 12). Moreover, p53 protein 
levels seemed to have no effect on ΔNp63 transcription. So, we can conclude that likely 
ASPP2 did not directly repress ΔNp63 expression in transactivation assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 – Transcriptional activity of ΔNp63 promoter measured by Luciferase reporter assay, 
transfecting into H1299 cells growing in 24-well plate, 1 μg of ΔNp63-luciferase reporter construct in 
presence or absence of ΔNp63α (400 ng) and ASPP2-V5 (1 μg ) expression vectors and together with 6 ng of 
a renilla expression vector.  
 
In normal basal epithelial cells, ΔNp63α promotes proliferation through regulation of 
some target genes such as p21. Transcriptional activity of p21 promoter was measured by 
Luciferase reporter assay, by transfecting into H1299 ΔNp63α in the presence or absence of 
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ASPP2-V5 expression vectors. Luciferase activity was analysed from cell lysates 24h after 
transfection and using the same lysates, the result was confirmed by Western blotting analysis, 
using antibodies anti-V5 (ASPP2), anti-p63 and anti-βtubulin (loading control). When testing 
the transcriptional activity of p21 promoter by transfecting ΔNp63α in presence of ASPP2, we 
observed an increased ΔNp63α proportional to the increasing amounts of ASPP2, while neither 
ΔNp63 nor ASPP2 alone seem to have significant effect (Figure 13). 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 13 – Transcriptional activity of p21 promoter. In this luciferase reporter assay, was transfected into 
H1299 cells growing in 24-well plate, 200 ng of p21 promoter in presence or absence of ΔNp63α (100 ng) 
and ASPP2-V5 (400, 600 ng) expression vectors and together with 6 ng of a renilla expression vector.  
 
 
We then investigated whether ASPP2 could repress ΔNp63 expression at transcriptional 
level using p63 promoter mutants, a mutant of a p63 isoform that lacks the N-terminal 
transactivation domain (a longer reporter) and a mutant that lacks the binding site for β-
catenin, a protein studied by our group and that is known to activate p63 expression and also 
because ASPP2 can inhibit its expression (a shorter reporter). 
As we hypothesize that in the -740/+139 promoter there is a group of factors, still 
unknown, that prevent ASPP2 to repress the expression of ΔNp63, and Notch is a known-
repressor of p63, the first approach was to test the expression of Notch alone when transfected 
with both promoters. Transcriptional activity of -704/+139 and -404/+139 promoters was 
measured by Luciferase reporter assay, by transfecting into H1299 cells each promoter in 
presence or absence of Notch expression vectors and together with renilla expression vector 
(internal control). Luciferase activity was analysed from cell lysates 24h after transfection, and 
the analysis showed that Notch had no significant effect on the longer promoter but, 
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interestingly, Notch could repress the transactivation of the -404/+139 shorter promoter 
(Figure 14).  
 
 
 
 
 
 
 
 
 
 
Figure 14 – Effect of Notch on ΔNp63 mutant’s transcription determined by luciferase assay. 
Transcriptional activity of -704/+139 and -404/+139 promoters measured by transfecting into H1299 cells 
growing in 24-well plate 50 ng of each promoter in presence of Notch expression vectors and together with 6 
ng of a renilla expression vector.  
 
Considering the hypothesis that ASPP2 could have a role similar to Notch, we 
hypothesized that, in the shorter promoter, ASPP2 can inhibit the function of p63 (Figure 30). 
We tested ASPP2 alone on the same reporter mutants, as seen previously for Notch, and we 
verified that in the longer promoter ASPP2 had no significant effect (Figure 15, A); however, 
ASPP2 represses the transactivation of the promoter of the short ΔNp63 promoter only (Figure 
15, B). 
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Figure 15 – Effect of ASPP2 on transcription of both ΔNp63 mutants by luciferase assay. 
Transcriptional activity of -704/+139 (A) and -404/+139 (B) promoters was measured by Luciferase reporter 
assay, by transfecting into H1299 cells growing in 24-well plate 1 μg (A) or 200 ng (B) of the promoter in 
presence or absence of ΔNp63α (400 ng, A) and ASPP2-V5 (1 μg, A) expression vectors and together with 6 
ng of a renilla expression vector. Luciferase activity was analysed from cell lysates, 24h after transfection, 
and normalised on the signal from renilla and this is expressed as fold induction. 
 
In order to evaluate whether ASPP2 can repress ΔNp63 expression at transcriptional 
level in a squamous cell carcinoma cell line HSC3, we transfected cumulative amounts of 
ASPP2 alone on ΔNp63 promoter and analysed the expression of p63 and ASPP2 transfected 
by Western Blot (Figure 16). Transcriptional activity of ΔNp63 promoter was measured by 
Luciferase reporter assay, by transfecting into HSC3 cells growing in 24-well plate 200 ng of 
promoter in increasing amounts of ASPP2-V5 expression vector. Luciferase activity was 
analysed from cell lysates, 24h after transfection and the transfection was confirmed by 
Western blotting analysis, using antibodies anti-p63 and anti-actin (loading control). The 
results showed that the expression of p63 decreases in accordance with increased values of 
ASPP2, corroborating that ASPP2 can repress p63 function. 
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Figure 16 – Effect of ASPP2 on ΔNp63 transcription by luciferase assay. Transcriptional activity of 
ΔNp63 promoter was measured by Luciferase reporter assay, by transfecting into HSC3 cells growing in 24-
well plate 200 ng of promoter in increasing amounts of ASPP2-V5 expression vector and together with 6 ng 
of a renilla expression vector.  
 
3.3 ASPP2 regulates ΔNp63 transcriptional function 
As ASPP2 was shown to directly bind to p63, we decided to test whether ASPP2 in 
combination with the repression of ΔNp63 expression levels could also regulate ΔNp63 
transcriptional activity. We investigated ΔNp63 transcriptional activity, in the absence or 
presence of ASPP2, on Keratin-14, Keratin-10 and envoplakin target genes. By luciferase 
transactivation assay, we found that the transcription of all the three genes, K14, K10 and 
envoplakin, was induced by ΔNp63 expression, whereas ASPP2 had no significant effect. 
Nevertheless, ASPP2 expression is able to repress ΔNp63α ability to induce K14 (A) and K10 
(B) transcription, while it enhances ΔNp63α ability to induce envoplakin transcription (C). 
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Figure 17 – ASPP2 regulates ΔNp63 transcription on genes involved in epithelial differentiation. (A) 
K14 luciferase reporter assay in H1299 cells. Transcriptional activity of K14 (A), K10 (B) and envoplakin 
(C) promoters was individually measured by transfecting into H1299 cells growing in 24-well plate 200 ng of 
each luciferase reporter construct in presence or absence of ΔNp63α and ASPP2 (V5-tagged) expression 
vectors (concentrations indicated in the graphs) and together with 6 ng of a renilla expression vector, as 
internal control. Luciferase activity was analysed from cell lysates harvested 24h after transfection and 
normalised on the signal from renilla. Effective transfection of ΔNp63α and ASPP2 expression plasmids was 
evaluated by Western blotting analysis of the same lysates used for the reading the luciferase activity, using 
antibodies anti-V5 (ASPP2), anti-p63 and anti-βtubulin (loading control).  
 
3.4 Cross-regulation between ASPP2 and Notch/ΔNp63 pathways 
To test if ASPP2 and Notch could interact, we decided to investigate whether their 
expression levels could regulate Keratin-14 transcriptional activity. We evaluated the K14 
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transcriptional activity, in absence or presence of Notch/ASPP2 (Figure 18). Luciferase 
activity was analysed from cell lysates harvested 24h after transfection of the expression 
vectors and the result was evaluated by Western blotting analysis of the same lysates. We 
found that Notch expression induced the transcription of K14 and ASPP2 had no significant 
effect alone. Nevertheless, the transcriptional induction when ASPP2 was transfected with 
Notch was almost completely eliminated and so ASPP2 was crucial to inhibit the induction of 
K14 mediated by both p63 and Notch. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 – Effect of Notch and ASPP2 on K14 transcription by luciferase assay. Transcriptional activity 
of K14 promoter was measured by transfecting into H1299 cells growing in 24-well plate 200 ng of reporter 
construct in presence or absence of ΔNp63α and ASPP2 (V5-tagged) expression vectors (concentrations 
indicated in the graphs) and together with 6 ng of a renilla expression vector, as internal control. Luciferase 
activity was analysed from cell lysates harvested 24h after transfection and normalised on the signal from 
renilla. Effective transfection was evaluated by Western blotting analysis of the same lysates used for the 
reading the luciferase activity, using antibodies anti-V5 (ASPP2), anti-p63, anti-Notch and anti-βtubulin 
(loading control). 
 
3.5 Notch and p73 share communal target genes and they are both regulated 
by ASPP2 
We decided to focus on TAp73 because p73 and Notch have similar roles (Talos, F. et 
al., 2010). Transcriptional activity of Bax promoter was measured by Luciferase reporter 
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assay, by transfecting into Saos-2 cells the promoter in presence of TAP73/ΔNp63α and 
ASPP2 expression vector. Luciferase activity was analysed from cell lysates, 24h after 
transfection. In this analysis we verified, firstly,  that ΔNp73 and Tap73, both isoforms of p73, 
alone, can stimulate the transcription of Bax promoter; the TA isoform has a better effect on 
the activation of Bax and ASPP2 is effective only at high levels to promote the transcription of 
the reporter (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 – Effect of Tap73α/ΔNp73α and ASPP2 on Bax transcription by luciferase assay. 
 
 
After that, we tested the same conditions for Hey2 promoter, a Notch target gene. We 
analysed the transcriptional activity of Hey2, in presence of Tap73 or ΔNp73 alone and in 
combination with ASPP2 (Figure 20). We could verify that both isoforms can induce the 
transcription of Hey2 promoter, and the TA isoform has a better effect on the activation of the 
reporter, additionally high levels of ASPP2 only induces the transcription of the promoter. 
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Figure 20 – Effect of Tap73α/ΔNp73α and ASPP2 on Hey2 transcription by luciferase assay. 
Transcriptional activity of Hey2 promoter was measured by Luciferase reporter assay, by transfecting into 
Saos-2 cells growing in 24-well plate 200 ng of promoter in presence or absence of TAP73α/ΔNp63α and 
ASPP2-V5 (concentrations indicated in the graphs) expression vectors and together with 6 ng of a renilla 
expression vector. Luciferase activity was analysed from cell lysates, 24h after transfection and normalised 
on the signal from renilla and this is expressed as fold induction. Tap73α and ΔNp73α expression, both 
isoforms of p73 alone, induce Hey2 transcription. 
 
Since the absence of ASPP2 had a selective impact on the expression of some of the 
major Notch target genes, as Hey2, we tested if ASPP2 can have a direct effect on its 
transcription in transactivation assay. We transfected Hey2 promoter with increasing amounts 
of ASPP2 expression construct, in H1299 cells. Interestingly, ASPP2, which is not a 
transcriptional factor itself, can regulate Hey2 transcriptional activity when transfected alone. 
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Figure 21 – Effect of ASPP2 on Hey2 transcription by luciferase assay. Transcriptional activity of Hey2 
promoter was measured by Luciferase reporter assay, by transfecting into H1299 cells growing in 24-well 
plate 200 ng of the promoter in increasing amounts of ASPP2 expression vector and together with 6 ng of a 
renilla expression vector. Luciferase activity was analysed from cell lysates, 24h after transfection and 
normalised on the signal from renilla and this is expressed as fold induction.  
 
Afterwards, we analysed the expression of Hey2 and Bax, some of the most important 
p73 target genes, in presence of Tap73 isoform. Notch was capable to induce activation on the 
promoters, while Tap73 had no effect, contrary to the expression of TAp73 that when 
transfected with Notch could reduce its expression and decrease the transcription of both target 
genes (Figure 22). 
 
 
 
 
 
 
 
 
Figure 22 – Effect of Tap73α and Notch on Hey2 and Bax transcription. Transcriptional activity of Hey2 
and Bax promoters was measured by Luciferase reporter assay, by transfecting into Saos-2 cells growing in 
24-well plate 200 ng of promoter in presence or absence of TAP73α and Notch (concentrations indicated in 
the graphs) expression vectors and together with 6 ng of a renilla expression vector. Luciferase activity was 
analysed from cell lysates, 24h after transfection and normalised on the signal from renilla and this is 
expressed as fold induction.  
 
 
0
2
4
6
8
10
12
Fo
ld
in
g 
In
d
u
ct
io
n
 (
%
) 
TAp73α        -           10           -          10           10           10 
Notch           -            -          400       100         200         400               
TAp73α    -           50           -           50          50          50 
Notch        -            -         400        100        200        400               
Bax promoter Hey2 promoter 
Hey2 promoter 
 
 
50 
 
3.6 Effect of Notch and p73 on reciprocal target genes 
Given the apparent similarities between Notch and p73 target genes, we thought it would 
be interesting to make a brief study about both factors on reciprocal target genes. The next 
graph summarizes several experiments to check the effect of Notch, p73 and ASPP2 on Hey2, 
Bax, Hes1 and Hes5 promoters into Saos-2 cells. Interestingly, we could see that Notch 
induces Bax promoter – which is a known p73 target gene – and ASPP2 alone activates Hey2 
promoter. 
 
 
 
 
 
 
 
 
 
 
Figure 23 – Effect of Notch and Tap73 on reciprocal target genes. Transcriptional activity of Hes1, Hes5, 
Hey2 and Bax promoters was measured by Luciferase reporter assay, by transfecting into Saos-2 cells 
growing in 24-well plate 200 ng of each promoter in presence of ASPP2, Notch or TAP73α expression 
vectors and together with 6 ng of a renilla expression vector. Luciferase activity was analysed from cell 
lysates, 24h after transfection and normalised on the signal from renilla and this is expressed as fold 
induction. 
 
Hereafter, we focused only on Bax and Hey2 promoters and all possible combinations 
between ASPP2, Notch and Tap73 (Figure 24), to try to understand how ASPP2 can enhance 
or inhibit Notch transcription on some of its target genes.  
We verified that ASPP2, which is not a transcriptional factor itself, can regulate both 
Bax and Hey2 transcriptional activity when co-transfected with Tap73, more specifically on 
Bax promoter, or with Notch, on Hey2 promoter. Notch in combination with Tap73, can also 
induce the expression of Bax promoter, which is interesting, because Bax is known to be a p73 
target gene. These results showed that ASPP2 is a factor capable of influencing Notch 
transcriptional action and both Notch and p73 share communal target genes. 
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Figure 24 – Effect of ASPP2, Notch and TAp73 on Bax and Hey2 promoters. Transcriptional activity of 
Bax and Hey2 promoters was measured by Luciferase reporter assay, by transfecting into Saos-2 cells 
growing in 24-well plate, 200 ng of each promoter in presence of ASPP2, Notch or TAP73α expression 
vectors and their combinations and together with 6 ng of a renilla expression vector. Luciferase activity was 
analysed from cell lysates, 24h after transfection and normalised on the signal from renilla and this is 
expressed as fold induction. 
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Luca Tordella, unpublished data 
CHAPTER IV: DISCUSSION  
4.1 ASPP2 expression promotes formation of spontaneous squamous cell 
carcinoma 
Squamous cell carcinoma (SCC) is among the most common cancer worldwide (Zhang 
et al., 2011) and is a malignancy of epidermal keratinocytes. SCC is a common form of 
invasive skin cancer (along with basal cell carcinoma (BCC)) (Zhang et al., 2005) and ASPP2 
is generally expressed in squamous epithelium. In order to provide an in vivo model system to 
study the biological functions of ASPP2, ASPP2 Δexon3 mice were generated by our group. 
The results which follow have been performed by Luca Tordella, another member of Professor 
Xin Lu’s lab, and are shown here because of their relevance to the present study. 
Balb/c is one of the most used mouse experimental strains for preclinical research and 
because it has a very low spontaneous incidence of tumours, is a suitable tool for long term lab 
experiments (Jackson Laboratory, last update: June 2012). In an attempt to obtain viable 
ASPP2 Δexon3 mice and considering the variations between the different genetic backgrounds 
of inbred mice, ASPP2 mutant mice were inter-crossed to a Balb/c background and, 
interestingly, the pups were viable and born according to the Mendelian segregation (Figure 
25). 
 
 
 
 
 
 
 
 
Figure 25 – Birth rate for ASPP2 wild type, ASPP2 heterozygous and ASPP2 Δexon3. Birth rate for each 
of the three possible genotypes generated by the intercross between ASPP2 heterozygous mice is shown 
comparing the Mendelian expected frequency (in white) with the observed frequency (in black). No 
significant anomalies in the distribution of birth rates were observed. 
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Luca Tordella, unpublished data 
Luca Tordella, unpublished data 
The majority of the ASPP2 Δexon3 homozygous mice in the Balb/c background were 
therefore able to survive up to one year after weaning. Since there are abnormalities that affect 
CNS, the general survival rate after birth was nevertheless significantly reduced when 
compared with heterozygous and wild type littermates. Moreover, intriguingly increased 
mortality, this time in the adult age, was also observed for ASPP2 Δexon3 heterozygous 
(Figure 26) (Tordella L., unpublished data). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 – ASPP2 Δexon3 mice in Balb/c genetic background are viable, but their lifespan is reduced. 
General survival study showing the decreasing percentage of ASPP2 Δexon3, heterozygous and wild type 
mice. ASPP2 has a gene dosage effect on mice survival, as mice lacking of both alleles of wild type ASPP2 
die earlier than the ASPP2 heterozygous, and both have a poorer survival than the ASPP2 wild type mice. 
 
4.2 Reduction of ASPP2 induces development of spontaneous carcinomas  
The susceptibility to develop spontaneous tumours was evaluated in a study comparing 
mutant ASPP2 heterozygous and wild type mice. An important finding of this study was that 
all the tumours found in the ASPP2-deficient group were classified as epithelial tumours, also 
known as carcinomas, while more variation in the tumour spectrum was observed in the wild 
type cohort (Figure 27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 – ASPP2 wild type and mutant mice develop spontaneous epithelial tumours. The graph 
shows the percentage and the spectrum of tumour types spontaneously developed by wild type and 
heterozygous mice. 
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At macroscopic level tumours appeared as solid compact masses, occasionally capsulated, with 
some degree of vascularisation (Figure 28). 
 
 
 
 
 
 
Figure 28 – Whole view and H&E-stained sections from the periphery and center of an epithelial 
tumour harvested from an ASPP2 heterozygous mouse (scale bars values are indicated) (Tordella L., 
unpublished data). 
 
 
The morphological analysis of the tumoural masses was then complemented with 
immunohistological staining for several cell markers. The results showed that the tumour cells 
from ASPP2 Δexon3 homozygous and heterozygous mice did not express vimentin, a marker 
of mesenchymal cells. On the contrary, the expression of several keratins was detected in all of 
the tumours analysed from the ASPP2 mutant cohort. In particular, high levels of keratin-14 
(K14) and keratin-1 (K1) were found (Figure 8), both well-known markers to keratinocytes, 
whose pattern of expression is a factor for tumour progression in SCC (Choi et al., 2010). 
Tumours from the ASPP2 mutant mice also revealed marked expression of nuclear p63 
(Figure 8), another conventional marker for SCC. p63 expression in epithelial cancers was 
previously found to be elevated in cells with high proliferative capacity (Pietenpol, A. et al., 
2004) and it is essential for the development of most tissues in which it is expressed, as p63-
null mice exhibit profound developmental abnormalities of the skin, limbs and other epithelial 
tissues (Mills et al., 1999; Pellegrini, D. et al., 2001).  
However, it is indeed still not very clear why SCCs express both basal cells markers, 
such as Keratin-5/14 and p63, and differentiated squamous cell markers, such as Keratin-1/10. 
It is also unclear why SCC-initiating basal cells need to express differentiation markers, as 
Keratin-1. A possibility is that keratinocytes fail to switch off basal genes, as Keratin-14 and 
p63, during differentiation. Alternatively, SCC might develop from partially differentiated K1 
positive suprabasal cells, which are still considered partially dynamic, but committed to enter 
terminal differentiation within a short time frame. The distribution and intensity of ASPP2 
expression in normal stratified squamous epithelium indicates that ASPP2 is predominantly 
expressed in differentiated suprabasal keratinocytes rather than the proliferative keratinocytes 
of the basal layer (Pellegrini, D. et al., 2001). 
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Poorly differentiated SCCs are distinguishable from well-differentiated carcinomas 
because they contain more pleomorphic cells, and no keratinous pearls. Relaying on these 
assumptions, our morphological and immunohistochemical analysis indicated that the tumours 
found in the ASPP2 mutant mice, have all the features of poorly differentiated, highly 
proliferative SCCs. Furthermore, supported a role for ASPP2 in suppressing tumourigenesis 
and uncovered a possible critical and specific involvement in skin tumour formation. 
 
4.3 Cooperation between ASPP2 and p53 in tumour suppression  
ASPP2 stimulates the apoptotic function of the p53 family in vivo (Lu et al., 2006) and 
ASPP2 was previously identified as an interacting partner for a number of proteins, including 
p53 (Iwabuchi et al., 1994), binding to its evolutionarily conserved DNA binding domain 
(Gorina and Pavletich, 1996). 
Consistent with the previously characterised role of ASPP2 in regulating p53-mediated 
apoptosis (Samuels-Lev, O'Connor et al., 2001), we decided to test if the ability of ASPP2 to 
suppress SCC was mediated by the p53 tumour suppressor properties. In order to test this 
hypothesis, the kinetic of tumourigenesis was measured and we observed that in the absence of 
p53, earlier tumour formation was detected in the ASPP2 mutant mice, suggesting that the 
combined loss of ASPP2 and p53 can accelerate tumour onset (data not shown). Loss of just 
one allele of p53 accelerated the onset of tumour formation in ASPP2 Δexon3 mice, allowing 
the appearance of a significant number of tumours in these mice before they prematurely die 
for CNS defects. The observation that a single-gene disruption, as in the case of the ASPP2 
Δexon3 mice, can cause such a specific epithelial phenotype, suggests that ASPP2 might play 
an important role in the maintenance of the homeostasis of the epidermis. 
Other works showed that p53 mutations in carcinomas can be involved in tumour 
progression, as opposed to tumour initiation (Kemp, Donehower et al., 1993; Feldser, Kostova 
et al., 2010), indicating p53 loss may not be a critical step in SCC initiation, but mainly 
important for the progression of malignancy. Altogether, these observations support the 
existence of a co-operation between ASPP2 and p53 in tumour suppression in a more 
comprehensive way.  
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4.3.1 p63 expression is up-regulated in ASPP2-deficient cells 
In SCC, what has been shown to be a primary cause for tumour formation is the aberrant 
overexpression of the p53-family member p63 (ΔN isoforms) (Hibi, Trink et al., 2000), which 
is believed to be important for conferring proliferative potential and resistance to apoptosis in 
tumour cells (Chiang, Chu et al., 2009). p63 plays an important role in epidermal homeostasis 
by promoting the maintenance of the epidermal stem cells population in the basal layer of the 
skin, while opposing growth arrest and differentiation stimuli mediated by p53-p73 and Notch 
(Rocco, Leong et al., 2006). In order to maintain the homeostasis of the tissue, p63 activity has 
to be limited to the basal layer of the skin.   
Factors specifically expressed in the upper layers of the epithelium, such as Notch, are 
believed to be important to antagonise p63 expression and activity in these layers, therefore 
preventing cell-proliferation to take place and protecting their differentiated status. Consistent 
with this protective role, the depletion of Notch activity or expression from the skin has been 
shown to lead to formation of SCCs (Proweller, Tu et al., 2006). As in the tumours developed 
by ASPP2 transgenic mice, p63 was found highly and almost ubiquitously expressed; we 
decided to investigate whether ASPP2 could also have a role as physiological repressor of p63 
expression in the squamous epithelium. 
To test whether ASPP2 could be an important factor important for the maintenance of 
the epithelial homeostasis, we first examined ASPP2 expression in the normal stratified 
epithelium, comparing it with p63 expression. By co-immunofluorescence analysis, good 
levels of ASPP2 expression were detected in the adult human skin epithelium with a peculiar 
localisation, restricted to the spinous and granular layer, which contain exclusively 
differentiated cells (Figure 9). Interestingly, ASPP2 pattern of expression was mutually 
exclusive with the one of p63, as no expression of ASPP2 was detected in the basal layer of the 
skin, containing undifferentiated and proliferative cells, which is where p63 expression resides. 
These experiments could support that ASPP2 protein is present in the stratified squamous 
epithelium of the skin and therefore it is conceivable that its disappearance from this site might 
be a direct cause for SCC formation, as observed in the ASPP2 deficient mice. 
Additionally, this specific localised expression of ASPP2 in the differentiated strata of 
the epidermis, led us to hypothesise that ASPP2 might be a factor involved in the 
differentiation of the squamous epithelium. To address this hypothesis, we monitored how 
ASPP2 expression can be modulated during cell differentiation in primary mouse 
keratinocytes.  
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Remarkably, ASPP2 expression was found to be up-regulated during differentiation, 
alongside with envoplakin, a protein induced with terminal differentiation (Karashima, T. and 
Watt FM., 2002) and in an opposite trend with p63, marker of cell pluripotency (Davydova, 
DA et al., 2009) (Figure 10). In more detail, ASPP2 protein seemed to be absent from the 
undifferentiated keratinocytes, with abundant p63 expression, marker of cell pluripotency 
(Davydova, DA et al., 2009), for then appearing immediately after one day from the 
stimulation of differentiation, characterised by the induction of envoplakin expression, a 
protein induced with terminal differentiation (Karashima, T. and Watt FM., 2002). The 
appearance of ASPP2 expression corresponded to the decrease in p63 protein level, which 
became even more substantial after 5 days after the addition of Ca2+-rich culture-medium. This 
observation – that ASPP2 induction during keratinocytes differentiation was found 
concomitant with p63 down-regulation – combined with the previously assessed tissue-
localisation confined to the differentiated layers of the epithelium, indicates that ASPP2 is a 
bona fide marker of epithelial differentiation in the skin. In other words, these findings 
suggested that ASPP2 expression might be physiologically important in repressing p63 during 
skin development and in preventing p63 to be expressed throughout the upper layers of the 
adult skin. This hypothesis could explain why when ASPP2 expression is impaired, as in the 
ASPP2-deficient mice, we observed over-expression of p63 in the skin and spontaneous 
formation of SCCs (Figure 11). Consistent with this, p63 overexpression has been reporter as 
potential cause of SCC formation in human SCC (Senoo, Tsuchiya et al., 2001; Reis-Filho, 
Torio et al., 2002). 
Altogether these data served to investigate the causes of SCC formation in ASPP2 
mutant mice, indicating that ASPP2 plays an important physiological role in the maintenance 
of the squamous epithelium. ASPP2 oncosuppressor role in the epithelium is epitomised by its 
inhibition on ΔNp63 potentially oncogenic expression and as a consequence, ASPP2 is found 
down-regulated also in human SCCs. 
 
4.3.2 Role of ASPP2 in regulating p63 at transcriptional level 
Concerning p63 localisation in SCC we already know, from our own results with the 
ASPP2 mutant mice, as well as results from other groups, that p63 is expressed at very high 
level in the cells constituting the tumour mass. We have shown that ASPP2 can suppress p63 
expression in human SCC cell lines and its expression is down-regulated in SCC, indicating a 
possible physiological role for ASPP2 as a “guardian” of the squamous epithelium, whose role 
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is to prevent p63 over-expression and tumour formation. Since previous results were 
performed in adult tissue, our next important question was to investigate how ASPP2 can 
regulate p63 at transcriptional level. We started by checking whether ASPP2 could directly 
repress ΔNp63 expression. In this analysis we measured the transcriptional activity of ΔNp63 
promoter by transfecting ΔNp63-luciferase reporter alone and/or in combination with ASPP2. 
It is important to mention that ΔNp63, which we had found up-regulated in ASPP2-deficient 
cells, is the isoform representing the majority of p63 expressed in the basal layer of the 
epithelium (both in normal and in SCC cells) (Yang et al., 1998), where it drives the 
proliferation of basal keratinocytes, and it is also the isoform which is over-expressed in SCC 
(Proweller, Tu et al., 2006). In this assay, we could identify that ΔNp63 is capable of 
activating the expression of ΔNp63 promoter. This analysis was performed by luciferase 
transactivation assay in H1299, a human carcinoma cell line which expresses very low levels 
of both ASPP2 and p63. We observed that when ASPP2 was transfected in combination with 
ΔNp63 or p53, the luciferase activity shows no induction thus, we concluded that ASPP2 
seems to have no additive effect on ΔNp63 induction, but just on its own promoter. Our results 
therefore suggest that ΔNp63 is able to activate the expression of ΔNp63 promoter, and the 
p53 protein seems to have no effect on ΔNp63 transcription (Figure 12). So, we can conclude 
that ASPP2 does not directly repress ΔNp63 expression. 
In normal basal epithelial cells, ΔNp63 promotes proliferation through regulation of 
shared p53 gene targets, such as p21, and possibly through other pathways as well (Westfall et 
al., 2003). p63 is similar to p53 with regards to its ability to modulate specific genes that 
mediate cell cycle arrest and apoptosis – including BAX, p21 and PUMA (Mills, Alea A., 
2006). Therefore, we measured the transcriptional activity of p21 promoter by transfecting 
ΔNp63 in presence of ASPP2 and we observed an increased expression of ΔNp63 proportional 
to increasing amounts of ASPP2, while neither ΔNp63 nor ASPP2 alone seem to have no 
additive effect (Figure 13). 
Thereafter, we investigated whether ASPP2 could repress ΔNp63 expression at 
transcriptional level. We did not use the entire ΔNp63 promoter, but two deletion mutants, a 
longer and a shorter version, -740/+139 and -404/+139 promoters, respectively. Our hypothesis 
was that in the longer promoter there is a group of factors, still unknown, that prevent ASPP2 
to bind and repress the expression of ΔNp63 (Figure 29). 
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Figure 29 – Hypothetical model of the effect of the longer promoter (-740/+139). 
 
As it is known that Notch is a repressor of p63, our approach was to test the expression 
of Notch alone when transfected with -740/+139 and -404/+139 promoters. Our results showed 
that Notch had no significant effect on the longer promoter but, interestingly, could repress the 
transactivation of the -404/+139 shorter promoter (Figure 14). 
 
 
 
 
 
 
 
 
Figure 30 – Hypothetical model of the effect of the shorter promoter (-404/+139). 
 
Considering that ASPP2 could behave similarly to Notch, we hypothesized that, the 
shorter promoter does not have the factors that function as repressors of ASPP2 expression, 
and consequently ASPP2 can inhibit the function of p63 (Figure 30). To test this hypothesis we 
transfected ASPP2 alone with the same reporter mutants, as we did previously for Notch. We 
observed that with the longer promoter ASPP2 had no significant effect neither alone nor when 
co-transfected with ΔNp63 (Figure 15, A). Interestingly, and in accordance with Notch 
activity, ASPP2 represses the transactivation of the shorter promoter (Figure 15, B) and had 
about 40% inhibitory effect on the short ΔNp63 promoter only.  
In order to verify whether ASPP2 can repress ΔNp63 expression at transcriptional level 
and in a human SCC cell line HSC3, we transfected increasing amounts of ASPP2 alone with 
ΔNp63 promoter and, using the same lysate, we assessed the expression of endogenous p63 
and ASPP2 by Western Blot (Figure 16). We could verify that the expression of p63 decreases 
while the values of ASPP2 increase, proving further evidence that ASPP2 can repress p63 
function. In this experiment there was a problem with the loading control and, although the 
HSC3 cells might work better, they have lower transfection efficiency. Therefore, in the future, 
a squamous cell carcinoma cell line may be useful, but one with higher efficiency of 
transfection. 
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4.4 ASPP2 regulates ΔNp63 transcriptional function 
Keratins, the major structural protein of all epithelia, are a diverse group of cytoskeletal 
scaffolding proteins that form intermediate filament networks, providing structural support to 
keratinocytes that maintain the integrity of the skin. Expression of keratin genes is usually 
regulated by differentiation of the epidermal cells within the stratifying squamous epithelium 
(Chamcheu, Jean et al., 2011).  
ΔNp63, as a transcriptional factor, is implicated in the regulation of the expression of 
several genes involved in epithelial differentiation. Some of these genes, such as Keratin-14 
and Keratin-1, were found up-regulated in the tumours developed by the ASPP2-mutant mice 
(Figure 8). As ASPP2 was shown to directly bind to p53 and its family members, including 
p63, and to confer them binding selectivity onto specific DNA promoters (Samuels-Lev, 
O'Connor et al., 2001; Bergamaschi, Samuels et al., 2004), we decided to test whether ASPP2 
in conjunction with the repression of ΔNp63 expression levels could also regulate ΔNp63 
transcriptional activity. We therefore tested ΔNp63 transcriptional activity, in absence or 
presence of ASPP2, on some of its known target genes important for epithelial homeostasis, 
such as Keratin-14, Keratin-10 and envoplakin.  
This analysis was performed by luciferase transactivation assay in H1299 cell line and 
here we found that the transcription of all the three genes, K14, K10 and envoplakin, was 
induced by ΔNp63 expression, as expected, while ASPP2 had no significant effect when 
transfected by its own. However, when ASPP2 was expressed in combination with ΔNp63, in 
the case of K14 and Keratin10, the transcriptional induction due to ΔNp63 transfection was 
almost completely abolished and the transcription was brought back to basal levels (Figure 17 
A-B). In an opposite direction, the transcription of envoplakin was further stimulated when 
ASPP2 was added to ΔNp63 (Figure 17 C). This finding indicates that ASPP2, which is not a 
transcriptional factor itself, has no intrinsic capacity to transactivate the ΔNp63 target genes 
but, nevertheless, it can regulate ΔNp63 transcriptional activity on them. 
Interestingly, these results correspond to what we had previously observed in the mouse 
tumours characterised by decreased ASPP2 expression, which showed up-regulation of K14 
and K1 (Figure 8). Moreover, concerning envoplakin expression, we had also previously 
noticed that during differentiation of primary keratinocytes its appearance was concomitant 
with ASPP2 expression (day 1 upon addition of Ca2+), confirming that ASPP2 might 
realistically be involved in its induction (Figure 10). Remarkably, we found that ASPP2 could 
inhibit ΔNp63 activity on K10 and K14 promoters, two genes found up-regulated in SCC, and 
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conversely enhance ΔNp63-mediated transactivation of the envoplakin promoter, a gene up-
regulated during differentiation.  
 
Recent works from Dr Bergamaschi’s group (2006) have shown that the ASPP family 
inhibitory member iASPP is also important for epithelial homeostasis, being expressed 
exclusively in the basal layer of the squamous epithelium together with p63, regulating its 
transcriptional activity and promoting its expression (Chikh, Matin et al., 2011; Notari, Hu et 
al., 2011). Thus, ASPP2 and iASPP have different expression patterns in the stratified 
epithelium and generally opposite effects on p63 expression, indicating that similarly to what 
has been described for p53-mediated apoptosis, even in epithelial differentiation the presence 
of different members of the ASPP family of proteins in combination with p63 could lead to 
different outcomes, which are in this specific case a basal- (iASPP) or differentiated-cell fate 
(ASPP2) (Figure 31).    
 
 
 
  
 
 
 
 
Figure 31 – Proposed model for ASPP2-mediated suppression of SCC. The presence of ASPP2 in the 
suprabasal layers of the epithelium repress and prevent p63 expression in these areas of the tissue. In case of 
impairment of ASPP2 function the expression of p63 would not be switched off in the transitional population 
of partially differentiated (K1 expression) suprabasal keratinocytes, allowing them to keep proliferating and 
giving origin to uncontrolled cell expansion (dysplasia and then carcinoma). Further decrease in ASPP2 
expression levels could eventually favour formation of distant metastases (Notari M., 2011). 
 
4.5 Cross-regulation between ASPP2 and Notch/ΔNp63 pathways 
Notch is an important regulator of epithelial homeostasis and a repressor of p63. The 
Notch signalling pathway is one of the most studied because of its importance in both 
development and disease. In particular, Notch function is important for cell fate determination, 
perhaps the most critical biological process in tissue homeostasis and development. Notch 
signalling participates in the development of multicellular organisms by maintaining the self-
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renewal potential of some tissues and inducing the differentiation of others (Raj K., Radtke F., 
2003; Proweller, Tu et al., 2006). 
In the epidermis the lack of Notch activity leads to tumour formation, making Notch a 
tumour suppressor protein (Proweller, Tu et al., 2006). In fact, in skin squamous epithelium, 
one of the principal ways by which Notch has a pro-differentiation role is by its ability to 
antagonise the expression and the activity of p63, whose role is to sustain the self-renewal of 
basal keratinocytes. Notch and p63 have therefore opposite roles in the epidermis and the 
balance between their activities and expression is critical for a correct epithelial homeostasis. 
ASPP2 has been originally characterised as a factor able to confer gene target selectivity, 
as shown for p53, p63 and p73 (Bergamaschi, Samuels et al., 2004), suggesting that it might 
also work with Notch in a tissue specific manner in skin. Since ASPP2 has a biological 
significance in the squamous epithelium, our group decided to test if ASPP2 and Notch 
pathways could physically and functionally interact. There are results showing that ASPP2 and 
Notch are co-expressed in the differentiated layers of the stratified epithelium and in the same 
cells in tumours. The consequences of ASPP2 and Notch interaction were also analysed, and it 
was found that the lack of ASPP2 resulted in deregulated Notch activity (Tordella L., 
unpublished data). 
The Notch pathway regulates cell fate and differentiation through cell-cell 
communication (Kopan R. et al., 2009) and Keratins-14 are expressed in undifferentiated and 
proliferative keratinocytes in the basal cell layer. Nakagawa’s group (2010) reconstituted the 
squamous epithelium in culture and found that Notch inhibition suppressed sharply epithelial 
stratification as well as early and late differentiation markers without affecting basal cell 
marker, i.e., K14 expression and proliferation (Nakagawa H. et al., 2010). These data suggest 
there is canonical Notch signalling in the early stages of squamous epithelial differentiation.  
To better understand this interaction, we decided investigate whether ASPP2 combining 
with the Notch expression levels could also regulate Keratin-14 transcriptional activity. Then, 
we tested K14 transcriptional activity, in absence or presence of Notch/ASPP2 on the target 
genes (Figure 18). Here, we found that the transcription of K14 was induced by Notch 
expression, while ASPP2 had no significant effect when transfected alone. Nevertheless, when 
ASPP2 was transfected with Notch, the transcriptional induction due to Notch transfection was 
almost completely abolished and the transcription resulted in basal levels. The same effect 
appeared when ASPP2 was transfected with ΔNp63, as we already discussed in the previous 
section. We can conclude that the presence of ASPP2 is crucial to inhibit the induction of K14 
mediated by both p63 and Notch. 
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4.6 Notch and p73 share communal target genes and they are both regulated 
by ASPP2 
Cell cycle control is paramount in maintaining normal growth and differentiation of cells 
and both p53 and p73 are important tumor suppressor genes that regulate the cell cycle via 
apoptosis and cell cycle arrest. Although the p73 protein does not function as a traditional 
tumor suppressor gene, its high level of sequence homology with the DNA-binding domains of 
p53 enables p73 to transactivate p53-response genes, resulting in cell cycle arrest, DNA repair 
and apoptosis (Li, G. et al., 2012). 
The p53 family member p73 is known to be an important mediator of apoptosis in 
response to DNA damage, chemotherapy, and other stimuli (Urist et al., 2004). Nevertheless, 
mutation of p73 is not observed at a significant frequency as it is in p63 in human cancers and, 
additionally, despite their remarkably similar structures, p63 and p73 appear to regulate largely 
non-overlapping sets of cell-cycle regulatory genes (Melino et al., 2003; Ellisen, L. et al., 
2006). Furthermore, a significant prevalence of p73 overexpression has been found in 
numerous different tumour types including tumours of breast, neuroblastoma, lung, colon, 
stomach, oesophagus, colon carcinoma and head and neck squamous carcinoma. Importantly, 
patients with high global p73 expression had a worse survival rate than patients with 
undetectable levels (Slade, N. et al., 2004). 
Su’s group (2009) identified that TAp73 as a critical factor for neural stem cell 
maintenance. Indeed, the TAp73 isoform is more highly expressed than the ΔNp73 isoform in 
neural stem cells (Talos, F. et al., 2010). This phenotype is reminiscent of the identified role of 
TAp63 in maintaining stem cells in the dermis, which are necessary for wound healing and 
hair regeneration (Su, X. et al., 2009). As the Notch and p73 have similar roles; TAp73 
isoform is more highly expressed than the other isoform (Talos, F. et al., 2010); and we 
verified a better effect and a higher activation with TAp73 isoform than with ΔN isoform 
(Figures 19-20), later on, our group decided to focus on only one isoform, TAp73. Here we 
tested Bax transcriptional activity, in absence or presence of TAp73/ΔNp73 alone or in 
combination with ASPP2 on the target genes (Figure 19). We could verify that both isoforms 
can induce the transcription of Bax promoter, the TA isoform has a better effect on the 
activation of the reporter and ASPP2 clearly enhanced the ability of p73 to transactivate the 
Bax promoter at high levels (Figure 19). 
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After that, we tested the same conditions for Hey2 promoter, a Notch target gene (Fisher 
A. et al., 2004). We analysed the transcriptional activity of Hey2, in absence or presence of 
TAp73 or ΔNp73 alone or in combination with ASPP2 (Figure 20). We could verify that both 
isoforms can induce the transcription of Hey2 promoter, and the TA isoform has a better effect 
on the activation of the reporter, additionally ASPP2 only induces the transcription of the 
promoter at high levels. 
There are data that define a Tap73-Hey2 transcriptional pathway that, when disrupted, 
causes depletion of adult neural stem cells (Kaplan, D. et al., 2010; Flores, 2011). Having 
observed that the absence of ASPP2 had a selective impact on the expression levels of some of 
the major Notch target genes, as Hey2, we next tested if ASPP2 can have a direct effect on its 
transcription using transactivation assays. We transfected H1299 cells – chosen because of 
their high degree of transfectability – with luciferase reporter plasmids for Hey2 promoter in 
combination with different amounts of ASPP2 expression construct. Interestingly, ASPP2, 
which is not a transcriptional factor itself, can induce Hey2 transcriptional activity when 
transfected alone, however these are preliminary data and the mechanism is still unknown. 
Notch pathway has a broad fundamental role in cell fate determination and its outcome 
then acquires specific connotations in different tissues depending on the interactions with 
different environmental factors. As Notch has an important role in promoting differentiation in 
the skin, we analysed the expression of some of p73 major target genes, Hey2 and Bax, in 
absence or presence of TAp73. Notch was found able to induce activation of the promoters in a 
dose dependent manner, while Tap73 by itself had no impact on them. However, when Tap73 
was expressed together with Notch, it was able to modulate Notch capacity to transactivate its 
gene targets. In particular, Tap73 diminished the ability of Notch to transactivate Hey2 and 
Bax and, in the specific case of Hey2, the transcription almost returned to basal levels (Figure 
22). 
 
4.7 Effect of Notch and p73 on reciprocal target genes 
Notch pathway is notoriously important for being able to affect cell fate determination 
across a wide range of different tissues with outcomes that can be very different, such as 
committing cells to differentiation (in skin) or promote cell pluripotency (in brain) (Notari et 
al., 2011). This variety is due to Notch transcriptional selectivity producing differential 
combinations of genes being expressed for different tissues or cell types, according to the 
scope required. A study on the effect of Notch and p73 on reciprocal target genes was carried 
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out with ASPP2, Tap73 and Notch factors. Transcriptional activity of Hey2, Bax, Hes1 and 
Hes5 promoters was measured by Luciferase reporter assay, by transfecting into Saos-2 cells 
each promoter in presence of ASPP2, Notch or Tap73 expression vectors. The most interesting 
results, as explained above, were that Notch activates Bax promoter - which is known to be a 
p73 target gene - and this is consistent with results from Shen’s group in which they observed 
that when Notch is induced, a significant transcriptional up-regulation of the target gene Bax 
occurs (Shen J. et al, 2004); and the most interestingly is that ASPP2 alone activates Hey2 
promoter – as data are still preliminary, the mechanism is still unknown. 
ASPP2 belongs to a family of adaptor proteins which are able to confer gene target 
selectivity, as shown for the p53 family of transcriptional factors, eventually affecting cell 
decisions and behaviour. Based on this assumption, on the fact that deregulation in Notch 
pathway activity is observed in the ASPP2 Δexon3 mice and that the two proteins, ASPP2 and 
Notch were found co-expressed in same cells in vivo (Ohashi, Natsuizaka et al., 2011), there is 
a possibility for a direct interaction. Indeed, results from our laboratory showed that ASPP2 
and Notch not only co-localise in the nucleus, the site where transcriptional activity takes 
place, but they can also be shuttled there by the same stimuli (data not shown). 
Following the same reasoning, we focused on both promoters Bax and Hey2, and 
proceeded to all possible combinations between ASPP2, Notch and Tap73 (Figure 23). It was 
the first time that these results were observed with these promoters (Bax and Hey2) and in the 
specific Saos-2 cell line, so these results are preliminary and the mechanisms will be 
investigated later. Currently, the group has been interested in understanding mechanistically 
how ASPP2 can enhance or inhibit Notch transcription on some of its target genes. Chromatin 
immunoprecipitation results showed that less active Notch can be found bound to the Hey2 
promoter in absence of ASPP2, suggesting that ASPP2 could act by increasing the binding 
affinity or the stability of Notch on certain promoters. 
For Bax and Hey2 promoters, we verified consistently that ASPP2, which, as already 
mentioned, is not a transcriptional factor itself and has no intrinsic capacity to transactivate, 
can regulate both Bax and Hey2 transcriptional activity when co-transfected with TAp73, more 
specifically on Bax and Hey2 promoters. We also verified that Notch in combination with 
TAp73, is able to increase its effect and together induce the expression of Bax promoter, which 
is interesting, because Bax is known to be a p73 target gene. Considering the implications of 
the ASPP2-Notch heterodimer formation, we verified again that ASPP2 is generally able to 
enhance Notch transcription of genes. In relation to the latter results, it is worth to mention that 
they seem to be cell line dependent, as we repeated the same experiments in H1299 cell line 
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and the results were slightly different. For example, in H1299 cells, ASPP2 did not activate 
Hey2 promoter, or TAp73, instead, it activated BAX and Notch, both in a lesser extent than in 
Saos-2 cells. 
TAp73α is induced by a wider variety of chemotherapeutic agents in different tumour 
cell lines and, conversely, blocking TAp73 function leads to enhanced chemoresistance, which 
is independent of the p53 gene status (Slade, 2004). Notch function, in general, is important to 
confer cell fate determination and its function is critically context dependent. Importantly, 
Notch activity seems to be generally regulated by cross-talks with pathways physiologically 
important for the homeostasis of each given tissue. There are evidences that support the 
existence of a possible cross-regulation between ASPP2 and Notch pathway, and also that both 
proteins are expressed in the differentiated layers of the squamous epithelium and the depletion 
of any of them from this compartment leads to the formation of spontaneous SCC with 
elevated expression of p63 (Sottocornola R. et al., 2010). These results support that ASPP2 is a 
factor capable of influencing Notch transcriptional programme and both Notch and p73 share 
communal target genes and they can be both regulated by ASPP2.   
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Chapter V: Conclusions and Outlook 
Having observed that ASPP2 and p63 gene expression are negatively correlated in the 
squamous epithelium, this would argue that in the adult tissue ASPP2 would be important to 
prevent p63 to be expressed in differentiated cells. Our data provides evidence that ASPP2 plays 
an important physiological role in the maintenance of the squamous epithelium. We have 
unequivocally demonstrated that one of ASPP2 roles in the epithelium is characterised by its 
inhibition of ΔNp63 (is the main p63 isoform expressed in the skin where it has a) potentially 
oncogenic expression and, as a consequence, ASPP2 is found down-regulated also in human 
SCCs. We showed that ASPP2-mediated suppression of SCC is achieved by repressing ΔNp63 
expression. p63 transcriptional factor is a master regulator of epithelial homeostasis, fundamental 
during development as well in the adult tissue to maintain the proliferative and stemness potential 
of the basal layer of the squamous epithelium. 
Interestingly p63, despite been predominantly a basal cell marker, can be still expressed at 
low level in suprabasal cells and knowing that an increase in its expression will result in cell 
proliferation, the maintenance of low levels of p63 expression in this site would be crucial to 
maintain the stability of the squamous epithelium and prevent any cancerous transformation. 
ASPP2 expression is induced upon keratinocytes differentiation and this coincides with a 
reduction in p63. On the contrary, during tumour progression, ASPP2 is downregulated from 
normal epithelium to SCC, while p63 is upregulated, defining a mutual exclusive expression 
pattern between the two proteins. Additionally, ASPP2 mode of action does not seem to be 
limited to the repression of p63 protein levels, but it also applies to the regulation of p63 
transcriptional program, by inhibiting p63-mediated transcription. This indicates that ASPP2 is 
not only a marker of cell differentiation, but also an active player in the process, mainly acting on 
p63 regulation. We can conclude that ASPP2 could be a gatekeeper of epidermal differentiation 
challenging p63 function. 
Notch protein is another key regulator of p63 and promotes cell differentiation in the 
squamous epithelium; it has been shown to be expressed in suprabasal keratinocytes and, once 
activated, is able to repress p63 expression (Nguyen, Lefort et al., 2006). Here we showed that 
ASPP2 is a factor capable of influencing Notch transcriptional programme, both Notch and p73 
share communal target genes and they can be both regulated by ASPP2.   
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ASPP2 is a factor able to confer transcriptional selectivity and our model shows that 
ASPP2 is a new important player in the cross-talk with Notch and this interplay could be 
important for the homeostasis of the squamous epithelial compartment. At present, despite the 
known importance of p63 in skin homeostasis and cancer, the molecular mechanisms controlling 
its expression and transcriptional regulation are not understood. Our results indicate that p63 and 
Notch expression and activity can be balanced in the squamous epithelium, providing a correct 
equilibrium between proliferation and differentiation.  
 
As the independent loss of ASPP2 or Notch protein from the squamous epithelium can lead 
to the formation of SCC in mouse models, hence the main mechanism lying behind this 
phenomenon might be the same – in the future, it could be interesting to explore this possibility, 
which would allow us to establish a fundamental link between our experimental findings and the 
human clinical data. It could be also interesting to produce expression constructs for the known 
mutated forms of Notch found in human SCC samples and see if they fail to interact with ASPP2 
(physically and functionally). In order to obtain more information about the mechanism, it would 
also be interesting to investigate the differences between the two cell lines, Saos-2 and H1299, 
since we found there is an effect Saos-2 dependent on p73 target genes. Consequently, it could be 
tested more Notch and p73 target genes for the study of communal target genes regulated by 
ASPP2. 
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